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ABSTRACT 
Cardiovascular disease (CVD), with atherosclerosis as its main underlying pathology, is the 
most prominent cause of death worldwide. Progression and rupture of atherosclerotic plaques 
lead to potential adverse pathological events such as myocardial infarction and stroke. 
Although largely successful, primary and secondary prevention strategies have thus far been 
insufficient in minimizing the vast consequences of atherosclerotic disease progression on 
global health. Abdominal aortic aneurysm (AAA) disease shares a similar risk profile with 
atherosclerosis. A consequence of undiagnosed AAAs can be their subsequent rupture, which 
up to 90% of patients will not survive.  
In both atherosclerosis and AAA, treatment and prevention are complicated by the fact that 
they progress silently and rarely lead to significant health impacts in their early stages. In 
addition, different pathological processes are known to be of importance as the diseases 
progress. These are also affected by patient-specific genetic and environmental risk factors. It 
would therefore be of benefit to find better ways of stratifying patient-specific disease risk and 
develop novel treatments. In the past decades, non-coding RNAs have emerged as powerful 
disease regulators in CVD and have been implicated as disease biomarkers in several research 
fields. In this thesis, we have sought to: (1) identify novel long non-coding RNAs (lncRNAs) 
involved in late-stage atherosclerotic disease and AAA, (2) establish techniques of their 
targeted delivery to affected vasculature, and (3) identify novel microRNA biomarkers of AAA 
with direct roles in disease development and progression.  
In study I, we have identified lncRNA MIAT as a novel regulator of vascular smooth muscle 
cell (VSMC) dynamics in carotid atherosclerotic disease, with positive effects on their survival 
– a beneficial trait in late-stage disease. Its effects on earlier disease stages were however 
detrimental through regulation of VSMC phenotypic switching into macrophage-like 
phenotypes and through regulation of macrophage-specific processes. In study II, we 
identified the lncRNA NUDT6, the natural antisense transcript of FGF2, to be up-regulated in 
fibrous caps of vulnerable vs stable plaques. NUDT6 was also up-regulated in AAA vs control 
aortic tissues. In experimental animal models of atherosclerosis and AAA, FGF2 de-repression 
by the way of NUDT6 inhibition had a beneficial effect on disease phenotypes and was 
successful in limiting the progression of these diseases. In studies II and III, we successfully 
used drug-eluting balloons to deliver therapeutics to the abdominal aorta of the translational 
mini-pig model of AAA. In addition, in study III, we observed beneficial effects of lenvatinib 
(VEGF-signaling inhibitor) on experimental AAA disease phenotype through positive effects 
on VSMC contractility and decreased diameter growth. Finally, in study IV, we identified 
miR-15a-5p as a novel disease biomarker of AAA. We showed miR-15a-5p to be relevant in 
AAA pathogenesis through its ability to modulate VSMCs into more inflammatory 
phenotypes, and its inhibition was able to limit experimental murine AAA diameter growth. 
In conclusion, our studies not only confirm that non-coding RNAs are promising targets for 
treatment of CVD, but also underline the translational feasibility of their use.

 
 
LIST OF SCIENTIFIC PAPERS 
 
This thesis is based on the following publications and manuscripts: 
* = shared first authorship 
I. Long non-coding RNA MIAT controls advanced atherosclerotic lesion 
formation and plaque destabilization. 
Fasolo F*, Jin H*, Winski G*, Chernogubova E, Pauli J, Winter H, Li DY, 
Glukha N, Bauer S, Metschl S, Wu Z, Koschinsky M, Reilly M, Pelisek J, 
Kempf W, Eckstein HH, Soehnlein O, Matic L, Hedin U, Bäcklund A, 
Bergmark C, Paloschi V, Maegdefessel L. Circulation. 2021;144:1567–1583. 
 
II. Inhibition of long non-coding RNA NUDT6 enhances smooth muscle cell 
survival during vascular disease development. 
Winter H, Winski G, Chernogubova E, Busch A, Bäcklund A, Pauli J, 
Paloschi V, Rykaczewska U, Soehnlein O, Eckstein HH, Matic L, Hedin U, 
Boon RA, Jin H, Maegdefessel L. Manuscript. 
 
III. Lenvatinib halts aortic aneurysm growth by restoring smooth muscle cell 
contractility. 
Busch A, Pauli J, Winski G, Bleichert S, Chernogubova E, Metschl S, 
Winter H, Trenner M, Wiegering A, Otto C, Fischer J, Reiser J, Werner J, 
Roy J, Brostjan C, Knappich C, Eckstein HH, Paloschi V, Maegdefessel L. 
JCI Insight. 2021;6(15):e140364. 
 
IV. microRNA-15a-5p regulates progression of abdominal aortic aneurysms 
and can be utilized as a circulating biomarker of disease prevalence and 
phenotype. 
Winski G, Chernogubova E, Busch A, Eken S, Jin H, Lindquist Liljeqvist M, 
Khan T, Bäcklund A, Paloschi V, Roy J, Hultgren R, Brostjan C, 
de Boorst GJ, Sachs N, Eckstein HH, Boon RA, Spin JM, Tsao PS, 
Asselbergs FW, Maegdefessel L. Manuscript. 
 
 
  
RELATED PUBLICATIONS 
 
Proteoglycan 4 Modulates Osteogenic Smooth Muscle Cell Differentiation during 
Vascular Remodeling and Intimal Calcification. 
Seime T, Akbulut AC, Liljeqvist ML, Siika A, Jin H, Winski G, van Gorp RH, Karlöf E, 
Lengquist M, Buckler AJ, Kronqvist M, Waring OJ, Lindeman JHN, Biessen EAL, 
Maegdefessel L, Razuvaev A, Schurgers LJ, Hedin U, Matic L. 
Cells. 2021 May 21;10(6):1276. 
Chitinase 3 like 1 (CHI3L1) is a regulator of smooth muscle cell physiology and 
atherosclerotic lesion stability. 
Tsantilas P, Lao S, Wu Z, Eberhard A, Winski G, Vaerst M, Nanda V, Wang Y, Kojima Y, 
Ye J, Flores A, Jarr KU, Pelisek J, Eckstein HH, Matic L, Hedin U, Tsao PS, Paloschi V, 
Maegdefessel L, Leeper NJ. Cardiovasc Res. 2021 Jan 20; cvab014. Online ahead of print. 
miR-29b mediates the chronic inflammatory response in radiotherapy-induced vascular 
disease. 
Eken SM, Christersdottir T, Winski G, Sangsuwan T, Jin H, Chernogubova E, Pirault J, 
Sun C, Simon N, Winter H, Bäcklund A, Haghdoost S, Hansson GK, Halle M, 
Maegdefessel L. JACC Basic Transl Sci. 2019 Feb; 4(1): 72–82. 
Local delivery of miR-21 stabilizes fibrous caps in vulnerable atherosclerotic lesions. 
Jin H, Li DY, Chernogubova E, Sun C, Busch A, Eken SM, Saliba-Gustafsson P, Winter H, 
Winski G, Raaz U, Schellinger IN, Simon N, Hegenloh R, Perisic Matic L, Jagodic M, 
Ehrenborg E, Pelisek J, Eckstein HH, Hedin U, Backlund A, Maegdefessel L. 
Mol Ther. 2018 Apr 4;26(4):1040-1055. 
MicroRNA-210 enhances fibrous cap stability in advanced atherosclerotic lesions. 
Eken SM, Jin H, Chernogubova E, Li DY, Simon N, Sun C, Winski G, Busch A, 
Bäcklund A, Österholm C, Razuvaev A, Renné T, Eckstein HH, Pelisek P, Eriksson, 
González Díez M, Perisic Matic L, Schellinger IN, Raaz U, Leeper NJ, Hansson GK, 
Paulsson-Berne G, Hedin U, Maegdefessel L. Circ Res. 2017;120:633–644. 
 
 
 1 
TABLE OF CONTENTS 
 
1 LITERATURE REVIEW ........................................................................................... 5 
1.1 Introduction to vascular disease ........................................................................... 5 
1.2 Vascular wall biology .......................................................................................... 5 
1.3 Atherosclerosis ..................................................................................................... 6 
1.3.1 Carotid artery disease and stroke ............................................................. 7 
1.3.2 Novel insights into the molecular landscape of atherosclerosis 
development and progression .................................................................. 9 
1.3.3 VSMC phenotypic switching ................................................................. 10 
1.4 Abdominal aortic aneurysms ............................................................................. 14 
1.4.1 Diagnosis and treatment ......................................................................... 15 
1.4.2 Pathogenesis of AAA ............................................................................. 16 
1.5 Animal models of vascular disease .................................................................... 17 
1.5.1 Mouse models of atherosclerosis ........................................................... 17 
1.5.2 Animal models of AAA ......................................................................... 20 
1.6 Gaps in knowledge ............................................................................................. 22 
1.7 Non-coding RNAs in vascular disease .............................................................. 23 
1.7.1 MicroRNA .............................................................................................. 23 
1.7.2 Long non-coding RNA .......................................................................... 25 
1.7.3 Delivery of ncRNA based therapeutics ................................................. 27 
2 RESEARCH AIMS .................................................................................................... 29 
3 MATERIALS AND METHODS .............................................................................. 31 
3.1 Study rationale .................................................................................................... 31 
3.2 Materials ............................................................................................................. 33 
3.2.1 Patient populations ................................................................................. 33 
3.2.2 Animals .................................................................................................. 35 
3.3 Animal models ................................................................................................... 36 
3.3.1 Mice ........................................................................................................ 36 
3.3.2 Mini-pigs ................................................................................................ 37 
3.4 Key molecular methods ..................................................................................... 38 
3.4.1 Genomics & bioinformatics ................................................................... 38 
3.4.2 Histology ................................................................................................ 39 
3.4.3 Cell culture ............................................................................................. 41 
3.4.4 RNA interactions .................................................................................... 42 
3.5 Statistics .............................................................................................................. 43 
3.5.1 Analysis of experimental data ................................................................ 43 
3.5.2 Analysis of transcriptomics data ............................................................ 43 
3.6 Ethical considerations ........................................................................................ 44 
 
 
 
2 
4 RESULTS AND DISCUSSION ............................................................................... 45 
4.1 Summary of key results ..................................................................................... 45 
4.1.1 Study I .................................................................................................... 45 
4.1.2 Study II ................................................................................................... 45 
4.1.3 Study III ................................................................................................. 46 
4.1.4 Study IV ................................................................................................. 46 
4.2 Key roles of VSMCs in vascular disease ........................................................... 48 
4.3 Treatment of vascular disease ............................................................................ 54 
4.4 Diagnosis and management of AAA ................................................................. 56 
4.5 Limitations and methodological considerations ................................................ 58 
4.5.1 Patient material ...................................................................................... 58 
4.5.2 Animal models ....................................................................................... 59 
4.5.3 Use of ncRNA therapies ........................................................................ 59 
5 POINTS OF PERSPECTIVE .................................................................................. 61 
6 CONCLUSIONS ........................................................................................................ 63 
7 ACKNOWLEDGEMENTS ...................................................................................... 65 
8 REFERENCES .......................................................................................................... 69 
 
  
 
 3 
LIST OF ABBREVIATIONS 
 
a-SMA 
AAA 
AngII 
APOE 
ASO 
BAPN 
BiKE 
CEA 
CVD  
DEB 
EC 
ECM 
ECST 
EVAR 
FFPE 
FISH 
GSEA 
HDL  
ILT 
ISH 
LDL 
LDLR 
lncRNA 
MIAT 
miRNA 
miR-15a 
MMP 
MVB 
 
Alpha smooth muscle actin  
Abdominal aortic aneurysm 
Angiotensin II 
Apolipoprotein E 
Antisense oligonucleotide 
ß-aminopropionitrile 
Biobank of Karolinska Endarterectomies 
Carotid endarterectomy  
Cardiovascular disease 
Drug-eluting balloon 
Endothelial cell 
Extracellular matrix 
European Carotid Surgery Trial (clinical trial) 
Endovascular aortic repair 
Formalin-fixed, paraffin-embedded 
Fluorescent in situ hybridization 
Gene set enrichment analysis 
High-density lipoprotein 
Intraluminal thrombus 
In situ hybridization 
Low-density lipoprotein 
Low-density lipoprotein receptor 
Long non-coding RNA 
Myocardial Infarction Associated Transcript 
MicroRNA 
miRNA-15a-5p 
Matrix metalloprotease 
Munich Vascular Biobank 
 
4 
NASCET 
 
NAT 
ncRNA 
ORA 
oxLDL 
PPE  
RBC 
ROS 
RT 
SMART 
SMC 
SM-MHC 
StAAAB 
TIMP 
UTMD 
VLDL 
VSMC 
 
North American Symptomatic Carotid Endarterectomy Trial 
Collaborators (clinical trial) 
Natural antisense transcript 
Non-coding RNA 
Overrepresentation analysis 
Oxidized low-density lipoprotein 
Porcine pancreatic elastase 
Red blood cell 
Reactive oxygen species 
Reverse transcriptase 
Second manifestations of ARTerial disease (cohort) 
Smooth muscle cell 
Smooth muscle myosin heavy chain 
Stockholm AAA Biobank 
Tissue inhibitor of matrix metalloproteinase 
Ultrasound targeted microbubble destruction 
Very low-density lipoprotein  
Vascular smooth muscle cell 
 
 5 
1 LITERATURE REVIEW 
1.1 INTRODUCTION TO VASCULAR DISEASE 
Cardiovascular disease (CVD) is the most common cause of death in developed countries [2, 
3]. CVD-related death amounts to 45% of deaths in Europe and approximately every third 
death worldwide [3]. CVD risk factors are widely known and include hypertension, 
hyperlipidemia, smoking, and type II diabetes [4, 5]. During the second half of the 20th century, 
it became increasingly known that CVD is largely driven by modifiable risk factors, and the 
focus for the treatment of CVD has shifted towards preventive measures among risk groups 
[6]. Atherosclerotic disease is responsible for a vast majority of CVD. Among these are 
coronary artery disease, cerebrovascular disease (e.g. stroke), and other diseases of the arteries 
(including aortic aneurysms) [7]. 
1.2 VASCULAR WALL BIOLOGY 
The vascular wall consists of three layers (‘tunicas’): intima, media, and adventitia (Figure 1). 
The intimal layer consists of endothelial cells (ECs) attached to the basal lamina, supported by 
the internal elastic lamina. The medial layer, rich in smooth muscle cells (SMCs) and elastin, 
is located between the internal and external elastic lamina. Medial elastin forms sheets 
(lamellae) between which proteoglycan-rich extracellular matrix (ECM) and SMCs reside. The 
outermost, adventitial layer, attached to the media through an external elastic lamina, consists 
mainly of a collagen-rich ECM produced by its inherent fibroblast cells. [8] 
 
 Figure 1. Basic histology of the arterial wall. Illustration by the author. 
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The elastic properties of the human arterial tree have evolved due to the pulsatile nature of 
human heart function. Without elastic arteries, the strain on the heart in systole would be 
significantly increased. Meanwhile, blood pressure would fall rapidly in diastole with 
subsequent flow decrease in distal arterioles. The elastic properties of the ECM enable storage 
of energy in the aortic wall during systole and later, through elastic recoil, discharge this energy 
in diastole. This physiological phenomenon ensures a more uniform flow throughout the 
cardiac cycle. Collagen and elastin, produced and deposited by SMCs, are the main 
components giving the ECM its mechanical properties. Upon intraluminal pressure increase, 
elastin allows the arterial wall to expand. At physiological pressure levels, only a small 
minority of collagen fibers are recruited. The fibers only become active upon further increased 
wall stretch, gradually reducing the elastic properties, yielding a tensile strength in the arterial 
wall. Other key components of the ECM are proteoglycans, which attract water and give 
resistance to compression, and glycoproteins which take part in ECM organization and act as 
anchors for the attachment of its cells. The ECM also allows for the binding and retention of 
molecules secreted by its inherent cells or delivered through circulation. These molecules, 
attracted and bound to proteoglycans, include growth factors, proteases, protease inhibitors, 
cytokines, and lipoproteins. [8, 9] 
1.3 ATHEROSCLEROSIS 
The pathogenesis of atherosclerosis consists of lesion formation, their slow progression, and 
subsequent luminal narrowing [9]. The development of these lesions, referred to as plaques, is 
known to begin early in life and develop slowly over the course of up to 50 years. Risk factors 
such as hypertension, hyperlipidemia, smoking, obesity, diabetes, and age are associated with 
increased prevalence and severity of atherosclerotic disease [10]. Atherosclerosis is driven by 
a progressive process of cholesterol-rich lipid accumulation, their oxidization, modification, 
and subsequent inflammatory response. While early-stage lesions can sometimes regress, 
intermediate and advanced lesions are of a chronic, progressive nature [11]. Different stages of 
atherosclerotic plaque progression are summarized in Figure 2. 
Development of ‘fatty streaks’, precursors of atherosclerotic lesions, starts in the innermost 
layer of the artery wall, the intima, through retention of low-density lipoprotein (LDL) particles 
from circulating blood. This process begins in childhood and early adolescence [11]. It 
commonly occurs at sites with disturbed flow (‘atheroprone regions’), such as branch points 
[12]. It was long believed that upon oxidative modification due to the presence of reactive 
oxygen species (ROS) or oxidizing enzymes, these oxidized LDL (oxLDL) particles trigger an 
inflammatory response. However, recently the scientific consensus has started to move away 
from oxLDL presence being necessary for atherosclerosis initiation [13], which may as well 
be mediated through the sole presence of non-modified native LDL or LDL aggregates. Intimal 
inflammation leads to activation of ECs, through several mechanisms, including upregulated 
expression of adhesion molecules, whereas SMCs contribute to this process by secreting 
chemokines and ECM components. Consequently, this leads to infiltration by immune cells – 
monocytes, lymphocytes, mast cells, and neutrophils. Monocytes transform into macrophages, 
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which, once activated through scavenger receptors in the presence of oxidized/native LDL, 
take up cholesterol droplets and form ‘foam cells’ [10, 11]. While the majority of foam cells 
were long thought to be solely of macrophage origin, recently, much focus has been put on the 
fact that vascular SMCs (VSMCs) can also become lipid-laden [14]. In response to cholesterol 
uptake, VSMCs can undergo a phenotypic shift, thereby losing their traditional contractile or 
synthetic phenotypic features and instead assuming the appearance of macrophage-like foam 
cells [15, 16]. 
Further, LDL accumulation and chronic inflammation promote cell apoptosis and lead to 
lesions with histopathologically evident ‘necrotic cores’. These more advanced atherosclerotic 
lesions, called ‘fibro-atheromatous plaques’, contain a subendothelial fibrous cap, composed 
of SMCs and collagen [17]. Further atherosclerotic stages are characterized by fibrous cap 
thinning, which makes them increasingly susceptible to rupture [18]. Through almost all 
disease stages, atherosclerotic plaques remain clinically silent. They only manifest themselves 
when their severity directly impedes blood flow, or through rupture of the fibrous cap, which 
leads to thrombus formation and either full or partial flow obstruction [19]. In both situations, 
the limited blood supply deprives the tissues of oxygen, leading to potential organ damage and 
dysfunction [11]. 
 
1.3.1 Carotid artery disease and stroke 
Stroke affects one in four people over their lifetime. Being the second leading cause of death 
and the third leading cause of disability in adults [20], it is one of the major diseases of the 
cardiovascular system with often dire consequences. It accounts for close to 5% of all 
disability-adjusted life-years lost [21] and 10% of all deaths worldwide [22]. Ischemic stroke 
is approximately twice as common as hemorrhagic stroke [20], and is defined as “an episode 
of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction” [23]. The 
leading cause of these infarctions is an occlusion of a cerebral artery [24], which quickly leads 
to irreversible tissue damage [25]. While other ischemic diseases such as myocardial infarction 
Figure 2. Progression of atherosclerosis and characteristics of different stages of the disease. Illustration by the author. 
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are caused by in situ plaque rupture leading to thrombosis and artery occlusion, ischemic stroke 
is most commonly embolic – either cardioembolic (due to atrial fibrillation or valvular heart 
disease) or atheroembolic (due to atherosclerotic disease in either carotid or vertebral arteries) 
[26]. Approximately 15 to 20% of ischemic strokes can be attributed to atherosclerotic carotid 
disease [27, 28]. 
Like other atherosclerotic plaques, carotid plaques can differ in degree and vulnerability [29]. 
Carotid stenosis is defined as a narrowing of the vessel lumen due to atherosclerotic plaque 
build-up, where progressive narrowing has been associated with increased risk of future 
ischemic stroke [30–33], although mainly in previously ‘symptomatic’ patients. Carotid 
stenosis is considered symptomatic upon simultaneous presentation with either stroke, transient 
ischemic attack (temporary period of symptoms similar to those of a stroke), retinal emboli, or 
amaurosis fugax (temporary unilateral vision loss caused by decreased blood flow to the retina) 
[34]. 
To limit the risk of future stroke, the plaque can be excised surgically through carotid 
endarterectomy (CEA) or stented (carotid artery stenting). CEA, where the plaque in the carotid 
artery is excised, is considered the gold standard treatment [35]. As is true for all surgical 
decision-making, the risk of the surgery needs to be weighed against the risk of future events, 
and in this case, the risk of stroke. Surgical treatment alone is not sufficient, and all patients 
without contraindications are treated with antiplatelet therapy, statins, and are recommended 
smoking cessation [29, 35]. In the 1990s, two large randomized control trials were performed 
to understand which patients with symptomatic carotid artery disease would benefit from 
undergoing CEA – European Carotid Surgery Trial (ECST [36]) and North American 
Symptomatic Carotid Endarterectomy Trial Collaborators (NASCET [37]). One significant 
difference between the studies was the method of stenosis quantification – NASCET compared 
the stenosed diameter to a distal, healthy part of the carotid artery, whereas ECST compared it 
to the full diameter of the artery at the stenosis site. The studies resulted in recommendations 
for CEA in patients with  >80% (ECST) or >50% (NASCET) stenosis grades (50% NASCET 
being equivalent to approximately 75% ECST). Current clinical guidelines refer to the 
NASCET classifications, recommending CEA in patients with ≥70% stenosis and suggesting 
it at 50-69% [38, 39].  
Asymptomatic carotid stenosis can in a limited number of cases be identified during routine 
examination (through the presence of an audible carotid murmur), but more commonly 
incidentally through radiologic imaging of the head and neck area [40]. These patients are also 
recommended medical treatment. However, the role of CEA in treatment of asymptomatic 
carotid stenosis is controversial, partly because the selection of patients, with expected benefit 
from surgery larger than the peri-surgical risk, is difficult [41]. Consensus, reflected in current 
clinical guidelines, is that the degree of carotid stenosis in these patients is not as clearly 
connected to future risk of stroke as it is in symptomatic patients [42]. However, this question 
is still lively debated and recent studies show that the surgical benefits in asymptomatic patients 
with severe carotid stenosis might have been underestimated [42]. 
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1.3.1.1 Plaque vulnerability and rupture 
“The major clinical consequences of atherosclerosis such as myocardial 
infarction or stroke are not a function of gradual narrowing of the lumen, 
but rather due to thrombotic events associated with acute rupture or erosion 
of an unstable plaque.” (Bennett et al. Circ Res 2016) [43] 
In past decades, vast efforts have been made to better understand which plaques contribute to 
adverse events such as myocardial infarction or stroke [44]. These events can in most cases be 
attributed to a thrombotic event due to rupture (65%) or erosion (30%) of an atherosclerotic 
plaque [43]. Remaining 5% are due to the presence of calcified nodules protruding through the 
fibrous cap of the lesion [38, 39]. In plaque rupture, a fissure in the fibrous cap exposes the 
highly thrombogenic plaque core to circulating blood, triggering formation of a thrombus [40]. 
Plaque erosion pertains to a local desquamation of the endothelial cell layer, triggered by 
changes in endothelial sheer stress due to changed flow conditions, and subsequent formation 
of neutrophil extracellular traps and thrombosis [41]. In absence of sufficient collateral 
circulation, the resulting occlusion or significant reduction of arterial lumen, either in situ or 
downstream through embolization, leads to ischemic tissue damage and often irreversible 
injury [49, 50]. ‘Vulnerable’ or ‘unstable’ plaques are defined as “thrombosis-prone plaques 
and plaques with a high probability of undergoing rapid progression” [42]. These plaques are 
characterized by features such as: thin fibrous cap poor in collagen covering a large necrotic 
core, fibrous cap rich in macrophages and few SMCs, neovascularization, and presence of 
intraplaque hemorrhage and spotty calcification [19]. Given that VSMCs have been implicated 
in most of these processes, they are intriguing candidates for development of novel therapeutics 
for stabilization of atherosclerotic plaques. Further, development of better risk stratification 
and optimized medical treatment strategies could provide new alternatives to CEA in certain 
patient groups. 
1.3.2 Novel insights into the molecular landscape of atherosclerosis 
development and progression 
The above-described mechanisms constitute the ‘traditional’ view of atherosclerosis etiology 
and development, which over the past decades has been progressively refined and modified to 
better reflect insights from studies using novel methods and exploring new ideas [13]. While 
the mechanisms of initial insults leading to the development of atherosclerotic plaques are still 
lively debated, the subsequent increase in immune cell infiltration within atherosclerotic 
plaques is considered a key event [49]. It is therefore understandable that for a long time the 
prevailing view had been that these externally recruited immune cells were the main 
contributors to the highly inflammatory milieu that characterizes advanced stages of 
atherosclerotic disease [51, 52]. Similar bias, based on histological images of human plaques, 
where high SMC content had been associated with more stable plaque phenotypes, drove the 
conclusion that proliferating SMCs, migrating from the medial layer of the artery into the 
intima, had solely a stabilizing role on plaques [51]. This unfortunate ‘guilt by association’ 
view has at least in part been caused by methodological limitations. As experimental methods 
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are refined, it allows us to challenge certain conclusions once considered evidence. This is very 
much the case when it comes to the role that VSMCs play in the development and progression 
of atherosclerotic plaques. 
Differentiated VSMCs of the medial layer of healthy arteries are of a contractile phenotype, 
characterized by the expression of contractile proteins such as SM-MHC (smooth muscle-
myosin heavy chain) and a-SMA (alpha smooth muscle actin) [53]. It has long been known 
that upon stimulation (in response to stress), for example by PDGF-BB, VSMCs can de-
differentiate into a proliferative, ‘synthetic’ phenotype, characterized by increased synthesis of 
ECM-proteins [53]. As VSMCs are characterized by their expression of contractile proteins, 
immunostaining and subsequent histological examination is the common method of spatially 
visualizing the location of VSMCs. However, this approach risks losing track of de-
differentiated VSMCs that have lost the expression of typical contractile proteins. The majority 
of VSMCs are localized within the medial layer, but under pathological conditions they can 
also be found within the intima [54]. Experimental insight into how VSMCs end up in the 
intimal layer, which involves crossing the internal elastic membrane of the vessel wall, had 
long been considered elusive [53]. The long-prevailing view, first suggested by Wisler in 1968, 
was that VSMCs proliferate and migrate from the medial into the intimal layer of the lesion 
[55]. 
Recent studies, made possible by the rapid advancement of single-cell sequencing and lineage-
tracing technologies, have challenged some of these ‘traditional’ views on VSMCs, and show 
that the temporal changes and the de-differentiation process of these cells to be much more 
complex than originally thought [56]. These studies confirmed that it is indeed almost 
exclusively local medial VSMCs that give rise to VSMC populations within the plaque [57], 
and showed that they do so in an oligoclonal fashion. In fact, up to 30-70% [56] of cells in 
experimental plaques are now believed to be of VSMC origin, and these populations seem to 
originate from only a small number of differentiated VSMCs [57–59]. 
1.3.3 VSMC phenotypic switching 
As mentioned above, the differentiated VSMCs within the medial layer are of a contractile and 
non-proliferating phenotype. Differentiation and maintenance of the contractile phenotype is 
under control of MYOCD, which together with SRF forms a complex able to bind to the ‘CArG 
box’, a DNA sequence expressed in promoters of contractile genes considered key markers for 
contractile phenotype [60, 61] such as MYH11 (encoding for SM-MHC), ACTA2 (encoding for 
a-SMA), CNN1 and CALD1. Promoters of contractile genes have also been shown to be under 
negative control of G/C-rich repressor elements [62, 63], and TGF-b control elements [64]. 
Phenotypic switching refers to de-differentiation and/or trans-differentiation of VSMCs into 
non-contractile phenotypes. Contractile VSMCs are responsible for many of the essential auto-
regulatory capabilities of muscular arteries and arterioles, and for maintaining their surrounding 
environment by secretion of ECM components [65]. Different phenotypes that VSMCs have 
been described to trans-differentiate into are summarized in Figure 3 and further discussed in 
the sections below. 
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1.3.3.1 Maintenance of VSMC contractile phenotype 
Given the key role of MYOCD in regulating contractile gene expression, much of phenotypic 
regulation has been described to occur via regulation of the aforementioned MYOCD-SRF-
CArG mechanism. KLF4, a key mediator of VSMCs phenotypic switching, has been described 
to interfere with SRFs ability to bind to MYOCD and interfere with the ability of MYOCD-
SRF to bind to the CArG-box of contractile genes [66]. In cooperation with p-ELK1, it can 
bind to the G/C repressor elements and recruit HDAC2, leading to epigenetic silencing via 
deacetylation of chromatin [67, 68]. p-ELK1, phosphorylation of which is activated by PDGF-
BB, is also an independent repressor of contractile phenotype as it competes with MYOCD for 
the same binding site on SRF [69]. KLF4 is not expressed in healthy differentiated VSMCs, 
but its expression can be activated by PDGF-BB through activation of Sp1, which possesses 
multiple binding sites on the KLF4 promoter [70]. Recent studies have revealed a possible 
equally important role of OCT4 in VSMC phenotypic regulation, with it having strikingly 
opposite roles to KLF4 in experimental models of atherosclerosis [71, 72]. Other factors 
described to repress MYOCD are the p65 subunit of NFkB [73], FOXO3a [74], and TCF21 
[75]. 
Figure 3. Vascular smooth muscle cell (VSMC) phenotypes and their proposed role in plaque stability. Foam cell and 
macrophage-like VSMCs have predominantly negative effects. Osteochondrogenic and synthetic VSMCs are context 
dependent and play both beneficial and detrimental roles. Mesenchymal cell-like and myofibroblast-like VSMCs are mostly 
considered protective. EC-like and adipocyte-like VSMCs have been described, but evidence on their roles in human 
atherosclerosis is still insufficient. Reprinted with permission from Grootaert & Bennett, Cardiovascular Research 2021 [56]. 
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1.3.3.2 Synthetic and myofibroblast-like VSMCs 
Synthetic VSMCs are characterized by the loss of contractile marker expression and an increase 
in synthetic, migratory, and proliferative capabilities. This phenotypic switch is relevant during 
all stages of atherosclerosis [76, 77]. The synthetic phenotype switch was early described to be 
required for the ability of the arterial vessel wall to react to injury and, through increased 
production of ECM components, either restore its integrity or limit irreparable damage [78, 
79]. While re-differentiation of these synthetic VSMCs has been shown in medial VSMCs after 
resolution of vascular injury [53], the de-differentiated VSMCs that have migrated to the intima 
seem to retain their synthetic properties on a more permanent basis, likely through continued 
stimulation due to the largely irreversible nature of atherosclerotic disease progression [56]. 
Recently, a single-cell RNA sequencing study of modulated VSMCs by Wirka et al. 
characterized a cluster of myofibroblast-like (or ‘fibromyocyte’) VSMCs [80]. These were 
defined by down-regulation of VSMC differentiation markers Tagln, Cnn1 and up-regulation 
of FN1, Tnfrsf1b (osteoprotegerin), as well as otherwise fibroblast-specific Lum, Dcn, Bgn. 
Further, they showed that this phenotypic switch was under the control of Tcf21, and its loss 
inhibited this phenotypic transition. During embryogenesis, TCF21 is known to control the 
divergence of coronary VSMCs and cardiac fibroblast lineages, and expression of TCF21 
seems to be required for fibroblast development [81]. Interestingly, while TCF21 expression 
levels are low in differentiated VSMCs, lineage-traced VSMCs within experimental lesions 
start to express Tcf21 in early stages, to thereafter localize mainly to the fibrous cap in advanced 
lesions [82]. In addition, TCF21 expression is increased in fibrous caps of stable lesions 
compared with ruptured plaques [82]. Thus, it remains to be seen whether the protective role 
previously assigned to ‘synthetic’ VSMCs may in fact be mediated through the presence of 
these myofibroblast-like VSMCs. 
1.3.3.3 Macrophage-like and foam cell-like VSMCs 
Under certain conditions, VSMCs can acquire a macrophage-like phenotype which can be 
found in both experimental and human atherosclerotic plaques [68, 83]. Upon cholesterol 
loading, cultured VSMCs up-regulate macrophage-specific inflammatory cytokines [68, 84], 
increase phagocytic behavior [84, 85], and decrease expression of SRF and MYOCD [84], 
responsible for maintenance of contractile phenotype. This transition is further characterized 
by loss of contractile markers and gain of macrophage markers such as CD68 and LGALS3 
[85]. Further, cholesterol loading of VSMCs has been shown to limit their ability to synthesize 
ECM-proteins [86], otherwise one of the main plaque-stabilizing effects of stimulated, 
synthetic VSMCs [87]. The pluripotency factor KLF4 is heavily involved in the regulation of 
VSMC trans-differentiation into this macrophage-like state [68]. 
The traditional view of a foam cell is of a macrophage that has undergone phagocytosis of LDL 
particles. While it was widely accepted that VSMCs exposed to LDL deposits can become 
lipid-laden, the extent and relevance of this VSMC phenotype was unclear [88, 89]. Lineage-
tracing studies have not only confirmed this effect to be of vast importance but also showed 
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that the majority of foam cells are in fact of VSMC origin [83, 90]. The exact mechanism for 
this phenomenon is not yet clear but could at least in part be explained by the fact that VSMC-
derived foam cells express much lower levels of cholesterol exporter ABCA1 compared to 
foam cells derived from macrophages [83]. Cholesterol overload can in turn trigger VSMC 
apoptosis [91] and VSMC-like foam cells have been found to line the necrotic core of 
experimental plaques [84], originally thought to comprise of mainly lipids and macrophages. 
While increasing evidence is pointing towards foam cell VSMCs, due to their limited capacity 
to clear cholesterol compared to their macrophage-derived counterparts, playing detrimental 
roles in atherosclerosis, the net impact of macrophage-like VSMCs is not entirely clear [56]. 
Even though these cells express macrophage-specific markers, recent evidence points towards 
the fate of these cells not being completely sealed. Firstly, this phenotype can be experimentally 
reversed in vitro through ‘lipid unloading’, by providing the cells cholesterol acceptors such as 
Apolipoprotein A1 and HDL (high-density lipoprotein) [84]. Secondly, even though 
macrophage-like VSMCs express macrophage-specific markers, their transcriptomes are vastly 
different from traditional macrophages [84]. Their closer resemblance has been noted to the 
Mox macrophage subtype [92], characterized by its lower phagocytic capacity compared to 
M1 and M2 macrophages [93]. Thirdly, expression of Lgals3 does not necessarily need to 
signify a functional macrophage-like phenotype [71]. The recent study by Alencar et al. [71] 
shows that LGALS3 might instead be a marker of a ‘transitional’ VSMC subtype. They show 
that the single-cell RNA sequencing cluster of this subtype, capable of subsequent progression 
into several different VSMC phenotypes, is the first one to acquire Lgals3 expression along 
with Ly6a/Sca1. The latter has been proposed to be a marker of primed VSMCs in intermediate 
states (‘mesenchymal cell-like’ VSMCs), which in response to inflammation can give rise to 
distinct VSMC subtypes present in atherosclerotic plaques [94]. 
1.3.3.4 Osteochondrogenic VSMCs 
Calcification of atherosclerotic plaques has historically been one of the signature characteristics 
of the disease. It has been used as a surrogate marker of atherosclerosis since the 1940s [95, 
96] and coronary artery calcium score is still a relevant clinical aid to help predict the risk of a 
future atherosclerotic coronary event (i.e. myocardial infarction) [97]. Originally thought to be 
a passive and degenerative phenomenon, vascular calcification was described by the 
pathologist Virchow in 1858 [98], who observed due to the presence of bone structure-like 
features likened it to an “ossification”. More than a century later, in 1983, Tanimura et al. [99] 
described VSMC-derived “matrix vesicle-like structures” to be involved in the calcification of 
atherosclerotic lesions. Today we know that vascular calcification is indeed a process driven 
largely by osteochondrogenic VSMCs and lineage-tracing studies have shown that a whole 
98% of osteogenic cells in experimental plaques are VSMC-derived [100]. Secretion of 
membrane-bound matrix vesicles is among the mechanisms proposed for VSMCs-mediated 
calcification [60]. It should be noted that medial and intimal calcification are considered 
different diseases, where the former is connected to vascular stiffness, hypertension, and heart 
failure, and the latter to the atherosclerotic consequences of arterial obstruction and plaque 
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rupture [60]. VSMCs with osteochondrogenic phenotypes are thought to be detrimental in the 
pathogenesis of late-stage atherosclerotic plaques [71]. The transformation into 
osteochondrogenic VSMCs has been described to be under the control of the osteogenic 
transcription factor RUNX2 [101–103], and KLF4-dependent [104]. However, the exact 
trigger for this switch has not been entirely elucidated. Seemingly, several signaling pathways 
seem to be involved, among these Wnt/b-Catenin [105, 106], BMP2 [107, 108], and VEGF 
[109]. Overall, the process looks to be driven by changes in the surrounding environment 
during atherosclerotic plaque progression. VSMCs affected by ongoing inflammation, 
oxidative stress and apoptosis have been shown to contribute to intimal calcification [60]. 
Currently, it is unclear whether VSMCs can transdifferentiate into an osteochondrogenic 
phenotype directly or if they first need to de-differentiate into a synthetic [110, 111], or perhaps 
even the intermediary LGALS3-expressing phenotype [71] mentioned in the section above 
[56]. 
1.3.3.5 Other VSMC phenotypes 
A number of other potential VSMC phenotypes have been described. In likelihood with the 
above-discussed phenotypes, they seem to be a result of VSMCs’ response to their surrounding 
environment. When exposed to shear stress in vitro, VSMCs have been described to adapt an 
endothelial cell-like phenotype, expressing markers such as vWF, CD31, VE-cadherin [112], 
under the control of Notch-signaling [113]. In in vitro adipogenic conditions, VSMCs can also 
transform into an adipocyte-like phenotype, characterized by the expression of adipsin and 
leptin [114]. The relevance of these phenotypes, and whether they are present in human 
atherosclerotic disease is however unclear [56]. 
1.4 ABDOMINAL AORTIC ANEURYSMS 
An arterial aneurysm is defined as a permanent, focal, full-thickness dilatation of an artery of 
more than 50% than its normal diameter. As the name suggests, abdominal aortic aneurysms 
(AAA) are located in the abdominal part of the aorta, and are the most common form of true 
arterial aneurysm, i.e. engaging the full-thickness of the arterial wall and its three layers: intima, 
media and adventitia [115]. Although the abdominal aorta has segments both above and below 
the renal arteries, AAAs preferably affect its infrarenal segment [116]. AAA-related death 
remains the 12-15th leading cause of death in USA, EU, and other European countries [117]. 
Risk factors include age, male sex, smoking, family history, and hypertension [118], while type 
2 diabetes has been shown to associate with a decreased risk [119, 120]. AAAs reported 
prevalence varies widely [121], although data from recent ultrasonography-based screening 
studies report a prevalence of 1-2% in 65-year-old men and 0.5% in 70-year-old women [122–
124]. AAAs are often described as ‘silent killers’, as they tend to be asymptomatic, and their 
diagnosis is often incidental or through systematic screening approaches [117]. The most feared 
consequence of AAA is its acute rupture, which carries a mortality of up to 90% [125, 126]. 
 
 
 
 15 
 
1.4.1 Diagnosis and treatment 
In clinical practice, an abdominal aorta with a diameter >30 mm is considered aneurysmal 
among men [127]. To date, there is no effective medical treatment for halting AAA progression 
or preventing acute rupture. Surgical repair can be performed, either through open surgery, 
with a prosthetic graft sewn into the aneurysmal part of the aorta, or through endovascular 
aortic repair (EVAR), where a stent graft is implanted into the aorta via luminal access through 
the femoral arteries. Compared to open surgery, EVAR is a considerably less invasive 
procedure, albeit not applicable to all patients, e.g. due to anatomical variations or certain 
comorbidities. Nonetheless, there still are significant peri-procedural and post-procedural risks 
such as: consequent endoleaks (incidence 20-50%; defined as “Persistent blood flow in the 
aneurysmal sac after deployment of the stent graft”), graft migration (up to 8%), and/or damage 
to the access arteries (9-15%). The risk of AAA rupture is positively correlated to the 
aneurysmal diameter, and size of >55mm is considered critical, as the risk of death due to 
rupture then exceeds the associated peri-surgical risk [118].  
In some countries, screening programs have been put in place to identify previously 
undiagnosed and potentially fatal AAAs. Screening programs have repeatably been shown to 
reduce mortality due to rupture of undiagnosed AAA [128] in a cost-effective manner [125, 
129, 130]. In Sweden, screening has been offered to 65-year-old men since 2006 and reached 
national coverage in 2015 [130]. However, many countries still struggle with broad 
implementation of screening (especially if they lack access to population-wide databases). As 
a consequence of decreases in the global prevalence of AAA, the efficiency of screening 
programs can be expected to follow. 
 
Figure 4. Anatomy of the aorta (left) and hallmark characteristics of human AAA (right). Illustration by the author. 
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1.4.2 Pathogenesis of AAA 
The majority of AAA patients suffer from advanced atherosclerosis and the abdominal aorta is 
a common site of advanced atherosclerotic lesions. Further, atherosclerosis and AAA share 
several key risk factors, including smoking, age, male gender, and family history. Whether 
atherosclerosis itself participates in AAA pathogenesis is still controversial [131]. A recent 
meta-analysis was able to show associations between changes in lipid metabolism-related 
genes and AAA risk [132]. Atherosclerotic changes and associated chronic inflammation could 
be hypothesized to contribute, at least in part, to the mechanical integrity loss of the vascular 
wall [118]. However, a clear causal relationship between these diseases has not been 
established. In contrast, certain evidence points towards them developing in parallel [133]. In 
support of this, the transcriptomes of AAA and atherosclerotic arterial disease show distinct 
patterns with little similarity [134].  
The infrarenal abdominal aorta carries certain predispositions for the incidence of aneurysm 
pathology due to its localization between the renal arteries and the iliac bifurcation. The 
infrarenal aortic wall lacks vasa vasorum in its medial layer [135]. Instead, most of the 
physiological transport to the medial layer occurs from the lumen through the arterial wall, or 
under pathological (aneurysmal) conditions through neo-angiogenesis from the adventitial 
vessels. The medial layer of the abdominal aorta is thus sensitive to hypoxia, and inherently 
thinner than for example the thoracic aorta. Meanwhile, the lower limitation by the iliac 
bifurcation introduces disturbances due to pressure-reflective waves [136]. 
Although we are still far from a complete understanding of the processes involved in AAA 
pathogenesis, histological and transcriptomic studies of human AAA, as well as molecular 
studies within its preclinical models have been able to elucidate many important aspects [137]. 
The hallmarks of AAA pathology are: a) disruption of VSMC plasticity and survival, b) 
degradation of ECM, and c) inflammatory cell infiltration [138]. Other characteristics are the 
presence of a chronic intraluminal thrombus (ILT) and adventitial inflammation and/or fibrosis 
[139]. Fragmentation of ECM through proteases is believed to be the constant driving factor in 
AAA development and progression [117, 140]. Key established drivers of ECM break-down 
are serine/cysteine proteases (e.g. plasmin, elastase, cathepsins) and matrix metalloproteinases 
(MMPs) [141–143].  
The significance of the ILT in AAA pathogenesis should not be understated, as it is prevalent 
in most AAA cases and has been shown to have direct influence over the local milieu within 
the vascular wall. As it is constantly renewed by circulating blood, it creates and upholds a 
highly proteolytic and oxidative environment, negatively affecting cells of the intima and 
media. This leads to the complete lack of an intimal layer (including ECs) in aneurysmal tissue. 
Further proof that the ILT is involved in AAA progression is that aneurysms with a present 
ILT are characterized by a thinner arterial wall, loss of medial elastic fibers and SMCs, and 
increased adventitial inflammation [139]. During its formation and turnover, the ILT recruits 
red blood cells (RBCs), platelets, neutrophils, fibrinogen, among others. The iron component 
of hemoglobin, released through RBC hemagglutination, contributes to oxidative stress 
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through the generation of free radicals [139]. Platelet activation and fibrin formation attract 
plasminogen, and tissue-plasminogen activator contributes to ECM break-down. Infiltrating 
neutrophils secrete urokinase-type plasminogen activator, elastase, and other proteases, as well 
as MMPs. MMPs are secreted as pro-MMPs and are cleaved into active MMPs by proteases 
(such as plasmin) or undergo auto-activation through interaction with ROS [144]. Elastase 
degrades fibrillar ECM components, whereas plasmin degrades adhesive glycoproteins (e.g. 
fibrillin and fibronectin) [117], and mobilizes latent TGF-b stored within the ECM. Loss of 
adhesive proteins in the media leads to detachment and apoptosis of mesenchymal cells, mainly 
SMCs (a phenomenon referred to as ‘Anoïkis’ [145]). Elastin fragmentation is responsible for 
progressive dilatation of the vessel, whereas collagen damage reduces the structural integrity 
(i.e. promotes rupture) [140]. 
Adventitial response to these events is characterized by chronic inflammation, fibrosis, and 
neo-angiogenesis. Macrophage accumulation assists in phagocytosis of iron stemming from 
RBC apoptosis in the luminal parts of the vessel wall. Fibrosis is largely a consequence of 
ongoing inflammation. Activation of latent TGF-b and TGF-b secretion by cells involved in 
the resolution of inflammation (e.g. M2 macrophages and regulatory T-cells) trigger an 
adventitial healing response. Consequently, adventitial fibroblasts produce collagens and other 
ECM components, which stabilizes the vessel wall and protects it from rupture [139, 146, 147]. 
Relative hypoxia of the medial and inner adventitial layers within a AAA context stimulates 
VEGF secretion by adventitial macrophages and medial SMCs, which drives neo-
angiogenesis. An extensive adventitial response can sometimes lead to so-called ‘inflammatory 
AAAs’, which, although rare, are characterized by adhesion of the aortic wall to neighboring 
organs [117]. 
1.5 ANIMAL MODELS OF VASCULAR DISEASE 
1.5.1 Mouse models of atherosclerosis 
“An ideal animal model of atherosclerosis resembles human anatomy and 
pathophysiology and has the potential to be used in medical and 
pharmaceutical research to obtain results that can be extrapolated to 
human medicine. Moreover, it must be easy to acquire, can be maintained 
at a reasonable cost, is easy to handle and shares the topography of the 
lesions with humans.” (Emini Veseli et al. Eur J Pharmacol 2017) [148] 
The idea for mimicking atherosclerotic disease in animals was first tried by Ignatowski in 1907 
[149]. By feeding rabbits with food normally consumed by humans (full-fat milk, eggs, meat), 
he could trigger the development of atherosclerotic plaques [150]. His work soon gave rise to 
several other studies into mechanisms of atherosclerosis through the development of animal 
models. In 1912, Anichkov and Chelatov reproduced his experiments, linking atherosclerosis 
to dietary cholesterol [151, 152]. Over the years, several different animal species have been 
used to study atherosclerosis [148]. Due to their small size, rapid reproduction, ease of genetic 
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manipulation, and low housing costs, mice have become the primary model to study 
atherosclerosis [148]. However, wild-type mice are not spontaneously susceptible to 
atherosclerosis development as their lipid profiles differ significantly from humans [148]. To 
better mimic cholesterol profiles of humans, transgenic mice were developed in the 1990s – in 
particular apolipoprotein E-deficient (Apoe-/- [153–155]) and LDL-receptor deficient (Ldlr-/- 
[156, 157]) mice. Apolipoprotein E (APOE) is a ligand for receptors that clear chylomicrons 
and very low-density lipoprotein (VLDL) particles [158], and its deficiency leads to sharp 
increases in plasma levels of these cholesterol fractions [148]. Similarly, LDL-receptor 
(LDLR) is a membrane receptor that mediates endocytosis of LDL-particles [159], levels of 
which are elevated in Ldlr-/- mice [148]. In humans, its deficiency is linked to a variant of 
familial hypercholesterolemia, a heritable dyslipidemic syndrome [160]. In both models, 
cholesterol levels can be further increased by feeding the animals a high-fat / Western-type diet 
rich in cholesterol [148]. The advantage of the Apoe-/- model is that lesions develop early, even 
on a normal (‘chow’) diet. A cholesterol-rich diet can further accelerate this, increasing lesion 
size and foam cell presence [161]. There are, however, certain disadvantages that warrant 
consideration. LDL is the primary cholesterol-carrying particle implicated in human 
atherosclerosis and only mildly elevated in Apoe-/- mice [148, 161]. APOE is also involved in 
other processes important for atherosclerotic plaque development, such as cholesterol efflux in 
macrophages [162]. Therefore, it also likely contributes to atherosclerotic plaques in other ways 
than its effects on circulating cholesterol profiles [148, 161]. All considered, Apoe-/- currently 
remains the most frequently used animal model for researchers studying atherosclerosis [148, 
161]. While other models have been described, Apoe-/- and Ldlr-/- mice have been the most 
popular in the past decades [161]. Their characteristics are briefly characterized in Figure 5. 
 
 
Figure 5. Characteristics of the two most popular mouse models of atherosclerosis. Figure reproduced with permission from 
Emini Veseli et al. [148]. Abbreviations: WD – western diet, ND – normal diet. 
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1.5.1.1 Plaque rupture in mouse 
Disadvantageous for virtually all mouse models is the absence of spontaneous plaque 
rupture [148], a hallmark of human atherosclerotic disease that heavily contributes to its 
associated morbidity and mortality [49]. The reason for this is not entirely known. The small 
size of mouse vessels is likely a contributing factor, as a decrease in vessel diameter leads to 
an exponential increase of surface tension, making rupture less likely [163].  
Several methods of inducing rupture of carotid plaques have been described, although none of 
them can truly mimic human pathophysiology [148]. An ideal model would correctly mimic 
human plaque morphology, have a balanced rate of rupture, result in the formation of a luminal 
thrombus, and have human-like complications (e.g. stroke) [148]. At least two models 
described in the past decades have closely approximated several of the mentioned 
characteristics, both in mice with Apoe-/- background. A popular model, described by Sasaki et 
al. in 2006 [164], consists of partial ligation of the left common carotid artery in 9-10-week-
old Apoe-/- C57BL/6J mice and simultaneous introduction of a high-fat diet, which induces 
neointimal hyperplasia and formation of lipid- and collagen-rich plaques. Four weeks later, a 
plastic collar is placed around the vessel, which in isolation had been described to lead to plaque 
formation [165]. Through the combination of these two techniques, the formation of vulnerable 
plaques can be induced, further mimicking human vulnerable plaques through intraplaque 
hemorrhage (31-47%), plaque rupture (29-63%), and formation of a fibrin-containing thrombus 
(17-42%) [148, 164]. Another interesting model was recently described by Chen et al. [166]. 
The authors performed ‘tandem’ partial-ligations (spaced 3 mm apart) of the common carotid 
artery in Apoe-/- C57BL/6J mice fed a high-fat diet. They created the model based on a 
computational fluid dynamics analysis, given that atherosclerotic plaques are known to develop 
in areas of low-shear stress, which is also the described mechanism driving plaque development 
and progression in the ligation + cuff model. After seven weeks, they were able to observe an 
impressive amount of human-like plaques – rich in lipids, macrophages/foam cells, having 
necrotic-cores covered with thin fibrous caps, displaying neovascularization and outward 
remodeling. In addition, some of these plaques presented with intraplaque hemorrhage (51%), 
rupture (32%), and the presence of a thrombus (undisclosed). Few studies have thus far sought 
to reproduce this model, but it might prove important in future studies of atherosclerosis if 
successfully reproduced. Nonetheless, certain limitations are likely to remain. One of the major 
challenges of these inducible plaque rupture models is that although local thrombosis occurs 
because of plaque rupture, embolic consequences such as stroke are more or less completely 
absent [148]. This underlines the fact that although the models may closely mimic specific 
characteristics of human disease, caution is needed when trying to extrapolate the results into 
clinically relevant conclusions. 
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1.5.2 Animal models of AAA 
To better understand AAA pathophysiology and the mediators involved, several mouse models 
of AAA have been developed [167, 168]. While human AAA specimens can be used for 
histological and transcriptomic studies, animal models allow experimental evaluation of 
research hypotheses in vivo. An ideal model should mimic the defining histological 
characteristics and course of human AAA pathology. Although none of the available mouse 
models fulfill these criteria, several have become popular within the AAA research field and 
are constantly refined [169]. Due to different mechanisms of AAA induction, and consequently 
different AAA characteristics, they can be used to focus on specific parts of AAA pathogenesis. 
Properties of main mouse models in relation to human disease are summarized in Table 1. Two 
AAA models popular within the field and relevant to this thesis are described below. The 
characteristics of the CaCl2 model are only briefly summarized for comparison purposes and 
have been thoroughly reviewed by Busch et al. [167, 168]. General limitations relating to the 
use of animal models and resulting methodological considerations are further discussed in 
section 4.5.2. 
 Human AAA PPE ePPE AngII CaCl2 
Fusiform growth + + * + * - + 
Fibrosis + + + + + 
Rupture + -  - (late *) # + (early) * - 
Wall dissection + - - + * - 
Slow, chronic development + - - - - 
ILT + -  - # - - 
IMT + - - + - 
Atherosclerosis + - - + - 
Calcification  + - - - + 
Angiogenesis + + - + + 
Elastic fiber loss + + + + (+) 
Inflammatory response + + - + + 
Table 1. Comparison of human AAA characteristics and common mouse AAA models. Adapted from Sénémaud et al. [167] and Busch et al. 
[168]. Abbreviations: ePPE/PPE – (external) porcine pancreatic elastase model, AngII – angiotensin II model, CaCl2 – CaCl2 model, ILT –  
intraluminal thrombus, IMT – intramural thrombus. # – present in ePPE in combination with anti-TGF-B treatment. * – introduced or 
exacerbated by BAPN. Clarifications: PPE/ePPE in combination with BAPN (ß-aminopropionitrile) leads to larger aneurysms. ePPE does not 
rupture unless combined with anti-TGF-B treatment, or BAPN (late rupture). AngII ruptures early and rupture rate is increased with BAPN. 
CaCl2 effect on elastic fibers is mostly concentrated to the external parts of the vessel. 
1.5.2.1 Angiotensin II infusion in Apoe-/- mice 
First described in 2000 [170], this model is today the most popular mouse model of AAA and 
the only well-established model of AAA rupture. Genetically modified Apoe-/- or Ldlr-/- adult 
mice are infused with high-doses of angiotensin II (AngII; 1000 ng/kg per minute) via a 
subcutaneous osmotic pump during a 28-day infusion period. During this period, most of the 
mice develop significant suprarenal aneurysms, and approximately 20% die due to rupture 
[171]. This model mimics certain aspects of human AAA disease, such as medial elastolysis, 
progressive aneurysm expansion, macrophage infiltration, and thrombus formation [172–175], 
but there are important differences to human AAA pathology. Firstly, the aneurysm 
pathogenesis has recently been highlighted to occur through intimal micro-tears, often in 
connection to ostia of major branch arteries [172]. This leads to the formation of an intramural 
hematoma and subsequently an intramural (rather than intraluminal) thrombus, which results 
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in the development of a so-called ‘dissecting AAA’ [175, 176]. Secondly, the supra-renal 
aneurysm location and quickly progressing luminal dilatation significantly contrast human 
disease [172]. Nonetheless, this model allows experimental studies of possible AAA rupture 
mechanisms, which is not possible using other models. Due to the use of mice on a 
hyperlipidemic genetic background, this model also allows studies of AAA in the presence of 
atherosclerosis. 
Recently, certain modifications to the original model have become increasingly popular [169]. 
One of these is the administration of AngII together with an anti-TGF-b antibody, allowing the 
use of normolipidemic C57BL/6 mice instead of the considerably more expensive genetically 
modified Apoe-/- or Ldlr-/- mice [177]. This modification also leads to a more rupture-prone 
AAA formation [178]. Another modification is the addition of BAPN (ß-aminopropionitrile), 
a lysyl oxidase inhibitor, to drinking water. While BAPN alone has been used to induce thoracic 
aortic dissection in juvenile mice, in combination with AngII infusion it increases rupture and 
dissection rates of the AAA model. When combined with PPE (described below), it leads to 
larger AAA diameters [168]. 
1.5.2.2 Porcine pancreatic elastase infusion in wild-type mice 
This model consists of transient infusion of porcine pancreatic elastase (PPE) into an isolated 
segment of the abdominal aorta. Originally developed in 1990 using Wistar rats [179], it was 
translated to mice in the early 2000s [141]. The procedure was later thoroughly described by 
Azuma et al. [180] and shown to reproduce well in C57BL/6 mice. The acute response (0-7 
days) involves transmural inflammation (involving ECs, SMCs, and fibroblasts) and neutrophil 
recruitment [167]. Aneurysm forms after approximately two weeks and is characterized by 
elastic and collagen fiber destruction, adventitial infiltration by macrophages, and increased 
MMP activity. Due to the impressive mimicry of human AAA progression, including medial 
elastic fiber breakdown, VSMC death, endothelial damage, and adventitial inflammation, this 
model has become extensively popular in experimental studies aiming to limit AAA 
progression. However, PPE-induced aneurysms eventually stabilize and seldom rupture, likely 
due to the transient nature of the initial stimulus. It must be noted that this mouse model of 
AAA is surgically challenging and requires extensive microsurgical expertise to achieve 
reproducible results. An alternative and more accessible to perform approach has been 
proposed, involving periadventitial administration of PPE (‘ePPE’ in Table 1) [181], but it 
results in significantly smaller and less reproducible aneurysms [167]. Recently, a new 
approach to the PPE model has been described [182]. Here, through a combination of topical 
application of elastase and systemic inhibition of TGF-b, significant and reproducible 
aneurysms were achieved with an approximate rupture rate of 50%. Interestingly, the authors 
argue that the rupture mechanism was not dependent on medial dissection, a significant 
limitation of the aforementioned AngII infusion model. In addition, upon histological analysis, 
most of the mice showed the presence of an ILT. If these findings can be replicated, this 
modified model could undoubtedly be of value for future experimental AAA research [183].  
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1.5.2.3 The need for large preclinical animal models 
The obvious limitation to the above-mentioned (and other) small animal models is that they do 
not entirely recreate the pathological basis for AAA human disease. As in other medical 
research fields, medical therapies proven to limit AAA progression in rodents have failed to 
affect human AAAs [184, 185]. This has called into question the translational feasibility of 
these models when aiming to develop novel therapeutic strategies. Murine models, although 
undoubtedly essential tools, should therefore primarily be seen as a first step of studying AAA 
disease in vivo. To aid the translation of preclinical findings into clinically relevant conclusions, 
efforts have been made to develop large-animal models of AAA [186]. Such models have been 
described in dogs [187], rabbits [188], and pigs [189], including miniature Yorkshire pigs 
[190]. In most of these proposed models, induction of a significant AAA was only possible by 
combining two or more stimulants (elastase, collagenase, CaCl2, or flow alternations). In 
addition, few (if any) of these models have been shown to be consistently reproducible in 
experimental studies, likely due to their complexity and high costs. To address this issue, our 
group has recently evaluated the PPE infusion model in wildtype and LDLR-/- Yucatan mini-
pigs [191]. While the wild-type animals did not develop significantly sized aneurysms (as had 
been reported before [192]), we were able to successfully induce relevant AAAs (>1.5-fold 
diameter increase) in LDLR-/- animals 28 days after instillation. The advantage of the Yucatan 
mini-pig over the majority of other animal species is the fact that their physiology can be 
considered more human-like, through similar body weight (approximately 75-80 kg), blood 
pressure, heart rate, and overall dimensions (size) of the cardiovascular system (heart and large 
arteries, such as the aorta and the carotid arteries) [191, 193]. 
1.6 GAPS IN KNOWLEDGE 
If left undiscovered or untreated, the potentially devastating consequences of AAA make it an 
important disease to study. The asymptomatic onset and progression of the disease can in many 
cases make rupture the debut symptom, which is associated with low survival. There is 
currently no pharmacological treatment for AAA and surgery remains the only option for 
patients at risk of rupture. During the last decade, multiple ncRNAs (non-coding RNAs) have 
been found to regulate vascular pathologies in general and AAA disease in particular [137]. A 
pharmacological (ncRNA-based) treatment would benefit patients who cannot or should not 
undergo surgery due to the risks involved. In many of these studies, experimental inhibition or 
overexpression of these molecules has been shown to halt AAA progression. Whether these 
findings can be translated into AAA human pathology remains to be seen. To facilitate this, 
novel preclinical models with better physiological and anatomical relevance to human disease 
will be of value.  
Similarly, given many intriguing reports on the involvement of ncRNAs in atherosclerosis, 
particularly in the regulation of VSMC fates, ncRNAs may emerge as potential novel targets 
for medical treatment of atherosclerotic disease. They could prove key to both understanding 
and impacting early atherogenesis, including genetic risk factors, but perhaps most importantly 
they could contribute to better management of late-stage atherosclerotic lesions. 
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In the past two decades, extensive efforts have been made to identify biomarkers of AAA 
disease and its progression [194]. Certain features such as ILT-volume or fluorodeoxyglucose 
uptake have been shown to correlate with AAA progression in retrospective studies [195, 196]. 
Peak wall stress has also been described as a predictor of AAA rupture risk [197, 198]. 
However, only circulating biomarkers can be considered feasible when looking for non-
radiological ways to diagnose AAA or identify patients at risk for AAA. Past studies of 
circulating biomarkers have focused on molecules involved in hemostasis (e.g. D-dimer [199], 
fibrinogen [200]) and arterial wall structural integrity (e.g. elastin [201, 202], MMPs and 
TIMPs [203–205]). Molecules involved in inflammation (e.g. IFNγ, interleukins [206]) and 
risk factors (e.g. serum triglycerides [207]) have also been studied, although given the severe 
atherosclerotic burden of many AAA patients, they are likely to be inherently less specific. 
Despite these efforts, no circulating protein biomarker of AAA has yet made it into clinical 
practice [194]. In addition, while females with AAA present with worse intervention outcomes, 
in contrast to men they do not benefit from ultrasound screening due to the lower prevalence 
of the disease [208–210]. 
Using ncRNAs as biomarkers has several unique advantages: many are tissue/cell-type 
specific, they are detectable with high sensitivity and specificity, one can perform network 
analysis (of ncRNA and putative mRNA targets), and they are stable in biofluids [211, 212]. 
The latter is especially true for the more recently characterized circular RNAs, which were not 
within the scope of this thesis. 
1.7 NON-CODING RNAS IN VASCULAR DISEASE 
The central dogma of molecular biology states that DNA is transcribed into mRNAs, which in 
turn are translated into proteins. Today, we know that while 70-90% of our genome is 
transcribed [213, 214], only approximately 2% effectively get translated into proteins [215]. 
Thus, considerable effort has been put into studying RNA species other than mRNA during the 
past two decades [61]. While the functions of tRNAs and rRNAs have long been known, other 
classes have emerged, previously considered ‘transcriptional junk’ [216, 217]. These are 
referred to as ncRNAs – as they do not code for proteins but rather extend their effects through 
transcriptional or post-transcriptional regulation [218]. These molecules have been 
characterized by their length, function, and genomic location. In this thesis, ncRNA subclasses 
microRNAs and long non-coding RNAs have been studied. Another type of ncRNA, studies 
of which have recently gained much traction, are circular RNAs [219]. 
1.7.1 MicroRNA 
Among the shorter ncRNAs, and currently the most well-studied, are microRNAs 
(miRNAs), ~22-nucleotide single-stranded RNAs. Although described already 1993 
in Caenorhabditis elegans [220, 221], it was not until the early 2000s that they were shown to 
be highly conserved across species and relevant in humans [222]. To this date, miRNAs have 
been shown essential for human development, cell differentiation, and homeostasis [223], and 
the human genome encodes for approximately 1000 miRNAs [224, 225]. Their deregulation 
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has been associated with the pathogenesis and progression of many diseases, and it is estimated 
that miRNAs regulate the translation of more than 60% of protein-coding genes [218]. During 
the last decade, many miRNAs have been described as highly relevant in CVD [225–227]. 
They have been shown to regulate SMC phenotype and apoptosis, matrix production and 
remodeling, TGF-b and inflammatory signaling, and EC function [226, 228, 229].  
 
The biogenesis of miRNA consists of several steps (Figure 6). Hairpin-shaped primary 
miRNA (pri-miRNA) transcripts are transcribed mainly by Polymerase II and then processed 
into miRNA precursors (pre-miRNA) by nuclear RNAse III enzyme Drosha [230] assisted by 
the protein DGCR8 [231, 232]. The remaining hairpin loop of the pri-miRNAs is then cleaved 
by cytoplasmic RNAse III enzyme Dicer to a specific length, typically 21-23 nucleotides [233, 
234]. This results in a mature miRNA duplex, of which one strand is loaded onto an AGO 
protein, most commonly Ago2 [235]. The strand preference of Ago2 is believed to be based on 
certain features of the 5’ nucleotide of the miRNA strand, although many miRNAs will exist 
in both strand (3p and 5p) variants [236–238]. The AGO-miRNA complex will then associate 
with target mRNA, forming the miRNA-induced silencing complex [235]. This is the primary 
regulatory function of miRNAs, as they initiate mRNA decay or exhibit translational repression 
through inhibition of ribosomal binding [239]. 
miRNAs are known as fine-tuners rather than absolute regulators in the sense that they can 
decrease protein production by approximately two-fold [240]. In addition, miRNAs are largely 
unspecific as they interact with mRNAs through complementary binding via their ‘seed 
sequence’, 6-8 nucleotides in length (usually located at nucleotides 2-8 from the 5’ end) [241]. 
In effect, a key characteristic of miRNAs is that they regulate not only specific genes but have 
often been found to have multiple targets within specific functional networks [242]. This 
Figure 6. microRNA biogenesis and main principles of function. Illustation by the author. 
 
 25 
property might be particularly interesting in the context of vascular disease, due to its highly 
sensitive nature [243], which has made the discovery of traditional drugs challenging [244]. 
In AAA, several miRNAs have been shown to regulate ECM-composition (miR-29, 181, 195), 
SMC survival (miR-21), SMC differentiation (miR-143/145 cluster), inflammation (miR-24, 
33, 181b), TGF-ß signaling (miR-181b, 195) as well as the expression of MMPs or tissue 
inhibitors of matrix metalloproteinases (TIMPs; miR-181b, 195, 205). Modulation of 
aforementioned miRNAs in experimental AAA models led to reduced AAA progression.  
1.7.2 Long non-coding RNA 
In recent years, focus has shifted towards ncRNAs with longer sequences. Among these are 
long non-coding RNAs (lncRNAs; >200 nucleotides in length). Compared to miRNAs, they 
are less abundant and less conserved among species [217]. In further contrast to miRNAs, 
which tend to exert their function through post-transcriptional inhibition of target mRNAs in 
the cytoplasm, functional lncRNA are found both in the cytoplasm and the nucleus. This gives 
them the ability to not only interact with other RNAs but also affect the chromatin dynamics 
and translation through RNA-protein interaction [245]. In addition, lncRNAs can regulate 
miRNA expression by acting as host genes for their transcription or by competing for 
complementary binding with miRNA target genes (‘miRNA sponges’) [246–248]. These and 
other key mechanisms of lncRNA function are summarized in Figure 7. 
 
  
Figure 7.  Different described action mechanisms of lncRNA. Reproduced with permission from Fasolo et al. [248]. 
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Only a handful of lncRNAs have thus far been implied in CVD, many more still likely to be 
discovered [249]. This is partly due to a relatively small number of lncRNAs with currently 
known biological functions (<1% of annotated lncRNAs [250]). In contrast to annotation of 
protein-coding genes, which can be identified by their open reading frame, lncRNAs lack 
known universal sequence features. Intriguingly, several lncRNAs have been described to 
encode short functional peptides of functional importance [251]. The relatively low abundance 
and weak evolutional conservation of lncRNAs further complicate the discovery and 
annotation of novel transcripts [252, 253]. Consequently, as new techniques are being 
developed, such as long-read sequencing technologies and novel annotation algorithms, our 
understanding of lncRNA biology will likely significantly increase [254]. 
During the past decade, key roles of lncRNAs in atherosclerosis and AAA have been 
characterized. Genome-wide genetic association studies have identified atherosclerotic 
disease-associated genetic variants in the Chr9p21 locus to overlap the sequence coding for 
lncRNA ANRIL [255]. Increased expression of ANRIL is considered atherogenic, and its levels 
in plaques (but also in circulation) correlate to atherosclerotic severity [256–258]. Even though 
ANRIL is one of the most studied lncRNAs in CVD, its exact molecular function remains 
elusive, and several mechanisms have been proposed [259]. ANRIL is also particularly 
interesting as increased levels of its circular isoform (circular RNA) seem to cause opposite 
effects compared to its linear counterpart, highlighting the intriguing complexity of the ncRNA 
landscape [260]. Several other lncRNAs have been described to functionally regulate VSMCs, 
e.g. lincRNA-p21 [261], SENCR [262], MALAT1 [263], SMILR [264] and CARMN [265]. The 
latter, originally thought to be a host gene for the miRNA-143/145 cluster, was recently 
described as able to directly (and independently of miRNA-143/145) interact with MYOCD, 
facilitating its binding of SRF [266]. CARMN is also a good example of a lncRNA with high 
tissue specificity, expressed solely in the vasculature [266]. 
Our group has recently described H19 to be the first lncRNA implicated in AAA development 
[191]. Its expression was increased in AngII and PPE mouse models of AAA, the PPE  
LDLR-/- Yucatan mini-pig model (described in section 1.5.2.3) and human AAA patient tissue. 
H19 was also shown to trigger transcription of HIF1α via recruitment of the SP1 transcription 
factor to the promoter region. In the cytoplasm, H19 interacted with HIF1α, induced p53 
activity, and was associated with increased SMC apoptosis and decreased SMC proliferation 
and migration.  
Due to their relative high tissue specificity, ability to regulate key features of VSMCs, and their 
apparent implication in CVD, lncRNAs shown to be involved in atherosclerosis and AAA 
pathogenesis seem like suitable candidates for potential treatment strategies and potential 
disease biomarkers [267]. 
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1.7.3 Delivery of ncRNA based therapeutics 
Therapies based on inhibition of disease-relevant ncRNAs are feasible by supplying 
antagomiRs (microRNA inhibitors) or GapmeRs (inhibitors of lncRNAs), which are synthetic 
antisense oligonucleotides (ASOs) that bind to the up-regulated ncRNA and silence it. 
Alternatively, by using lncRNA- or miRNA-mimics, it is possible to enhance the expression 
of down-regulated ncRNAs [267, 268]. 
One major disadvantage of such treatment strategies, utilizing systemic intravenous, 
subcutaneous or intramuscular injections of ncRNA-inhibitors, are the documented off-target 
effects of these ASOs on other organ systems. In fact, ncRNA-inhibitors tend to assimilate to 
a much greater extent in organs such as the liver, kidney, lung, and spleen than in the targeted 
cardiovascular system [269]. Therefore, tools and techniques for local or cell-type-specific 
delivery would be of great value to make such treatments feasible. In one such effort, our group 
has recently described local delivery of a miR-21 mimic using ultrasound-targeted 
microbubbles into carotid plaques to induce a more stable plaque phenotype [270]. 
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2 RESEARCH AIMS 
The overall objective of the thesis was to extensively evaluate the role and therapeutic potential 
of novel ncRNAs in vascular disease development and progression. We hypothesized that 
modulation of these (or previously described) ncRNAs through local delivery mechanisms 
might prove to be an efficient method to halt disease progression. In addition, we aimed to 
study the potential of ncRNAs (primarily miRNAs) as diagnostic and prognostic biomarkers 
for AAA disease. 
The specific aims were: 
Study I. To explore the functional role of long non-coding RNA MIAT in human 
atherosclerotic disease. 
 
Study II. To explore the functional role of a human disease NUDT6, a natural antisense 
transcript of FGF2, in experimental in vivo and in vitro models of vascular 
disease. 
 
Study III.  
a. To evaluate the potential protective role of multi-kinase inhibitor lenvatinib 
on AAA disease phenotype and progression. 
b. To evaluate the feasibility of targeted drug delivery to the aortic tissue in a 
translational mini-pig model of AAA disease. 
 
Study IV. To identify potential miRNA biomarkers of AAA disease and study their 
involvement in the pathogenesis of the disease. 
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3 MATERIALS AND METHODS 
3.1 STUDY RATIONALE 
For study I, we performed gene expression profiling in tissues from patients with advanced 
carotid artery atherosclerotic lesions from the Biobank of Karolinska Endarterectomies, 
comparing them to non-atherosclerotic iliac artery controls. We found increased expression of 
lncRNA MIAT (Myocardial Infarction Associated Transcript; previously also known as 
Gomafu). MIAT had previously been implicated in patients with myocardial infarction, as well 
as in endothelial inflammation in diabetic retinopathy. A subsequent separate analysis of an 
independent cohort of patient plaques from the Munich Vascular Biobank showed increased 
expression of MIAT in fibrous caps in ruptured/unstable (cap thickness ≤200 μm) compared to 
stable (cap thickness >200 μm) plaques. 
In study II, we employed a hypothesis-driven approach to look at natural antisense transcripts 
(NATs) of known growth factors that play key roles in both carotid atherosclerosis and AAA. 
While direct inhibition of growth factors is a clinically utilized therapeutic strategy for the 
treatment of certain conditions (e.g. cancer), there are scenarios where instead an increased 
expression of specific growth factors is desirable. We hypothesized that targeting the NAT, 
and thus a potential transcriptional and/or translational repressor of the growth factor in 
question, could be used to achieve this. In fibrous caps of stable and unstable/ruptured plaques 
from the Munich Vascular Biobank (described in the paragraph above) and in aortic tissues 
from AAA patients and healthy organ donors, we found FGF2 and its NAT NUDT6 to be 
differentially regulated in opposing directions. Expression of FGF2 was decreased in 
AAA/unstable plaques, whereas NUDT6 was increased. As we considered FGF2 to be 
beneficial in both AAA and advanced atherosclerosis, we wanted to study whether NUDT6 
inhibition could turn out to be a potential treatment strategy for stabilization of these diseases. 
Hypoxic mechanisms and associated angiogenesis have been implicated in AAA 
pathogenesis [271–273]. Hypoxia-induced VEGF signaling drives angiogenesis and is a 
known phenotypic modulator of SMCs [274]. Therefore, in study III, we employed a drug 
repurposing approach. Lenvatinib, a multiple kinase inhibitor developed as an anti-cancer 
medication, is known to target the main receptor of VEGF (VEGFR2) [275]. 
As the above approaches turned out successful in murine models, we attempted to bridge the 
translational gap between mice and humans, by using a more human-mimicking, novel 
LDLR-/- mini-pig models of atherosclerosis and AAA, recently described by our group. The 
therapeutic approaches attempted in studies II and III were also deemed promising candidates 
for local delivery through the use of drug-eluting balloons (DEBs). 
Finally, in study IV, we sought to identify disease-relevant circulating miRNA biomarkers for 
AAA through a non-biased approach using multiple large-sized cohorts of AAA patients with 
different characteristics, and controls. The need for such a study was identified based on the 
 
32 
fact that few such studies had been performed and validated on sufficiently large cohorts, and 
that few studies had attempted to directly show functional relevance of discovered miRNAs.  
Table 2. Overview of studied mechanisms, outcomes and methods in each of the studies. 
Study 
Target & studied 
disease Role in disease Animal models 
Experimental 
outcome Molecular methods 
I 
MIAT 
Carotid artery 
atherosclerosis 
Mediates VSMC 
phenotypic 
switching through 
induction of KLF4 
Apoe-/- Miat-/- 
C57BL6 mice 
(ligation+cuff) 
LDLR-/- Yucatan 
mini-pigs 
Inhibition 
reduces 
atherogenesis, 
increases  
experimental 
plaque 
vulnerability 
Laser-capture 
microdissection, MA, 
qPCR, WB, ISH/FISH, 
IHC/IF, RIP 
In vitro: RNA/plasmid 
(co)transfection, 
luciferase reporter 
assay cell fractionation, 
live cell imaging, 
primary cell isolation 
In silico: lncRNA-DNA 
target prediction 
II 
NUDT6 
Carotid artery 
atherosclerosis, 
AAA 
Inhibits FGF2; 
Detrimental to 
atherosclerotic 
plaque stability 
and AAA, through 
reduced 
proliferation of 
VSMCs 
Apoe-/- C57BL6 
mice (ligation+cuff,  
AngII AAA) 
C57BL6 mice (PPE 
AAA) 
LDLR-/- Yucatan 
mini-pigs (PPE 
AAA, DEB, UTMD) 
Inhibition 
stabilizes  
experimental 
plaques, 
augments AAA 
progression 
Laser-capture 
microdissection, MA, 
qPCR, WB, ISH, IHC, 
RNA-pulldown 
In vitro: RNA 
transfection, live cell 
imaging 
III 
VEGF-signaling 
(VEGFR2) 
AAA 
 
Mediates 
angiogenesis, 
phenotypic 
switching of 
VSMCs 
Apoe-/- C57BL6 
mice (ligation+cuff,  
AngII AAA) 
C57BL6 mice (PPE 
AAA) 
LDLR-/- Yucatan 
mini-pigs (PPE 
AAA, DEB) 
Inhibition 
through 
lenvatinib 
augments AAA 
progression, 
preserves SMC 
contractile 
phenotype 
MA, qPCR, WB, IHC/IF 
In vitro: live cell 
imaging, cell contraction 
assay, primary cell 
isolation 
In silico: Pathway ORA 
IV 
miR-15a-5p 
AAA 
Circulating 
biomarker; Inhibits 
proliferation of 
VSMCs, reduces 
transdifferentiation 
of VSMCs to an 
inflammatory 
phenotype 
Apoe-/- C57BL6 
mice (ligation+cuff,  
AngII AAA) 
C57BL6 mice (PPE 
AAA) 
Inhibition 
augments AAA 
progression 
MA, RNA-seq, qPCR, 
FISH, IF 
In vitro: miRNA-
transfection, live cell 
imaging 
In silico: miRNA-target 
prediction, GSEA 
Abbreviations: MA – microarray; RNA-seq – RNA sequencing; qPCR – reverse transcription quantitative polymerase chain 
reaction; WB – western blot; (F)ISH – (fluorescent) in situ hybridization; IHC – immunohistochemistry; IF – immunofluorescence; 
RIP – RNA immunoprecipitation; ORA – over-representation analysis; GSEA – gene-set enrichment analysis; PPE AAA – PPE 
perfusion AAA model, AngII AAA – AngII infusion AAA model; UTMD – ultrasound targeted microbubble destruction; DEB – drug-
eluting balloon. 
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3.2 MATERIALS 
3.2.1 Patient populations 
All material used for histological, gene expression and protein expression analyses of carotid 
atherosclerotic plaques stems from either the Biobank of Karolinska Endarterectomies (BiKE) 
or Munich Vascular Biobank (MVB). All material used for histological, gene expression and 
protein expression analyses of AAA in studies II and III stems from MVB. In study IV, 
material for histological analyses stems from MVB, material for gene expression stems from 
MVB and Stockholm AAA Biobank (StAAAB), patient plasma/serum stems from Second 
manifestations of ARTerial disease (SMART) cohort, Stockholm AAA screening cohort, 
StAAAB or Vienna AAA cohort. All patients provided written and informed consent approved 
by the responsible ethics committees at each site. 
3.2.1.1 Biobank of Karolinska Endarterectomies (BiKE) 
BiKE and its sampling protocols have been described in detail by Perisic et al. [276]. Briefly, 
patients with symptomatic or asymptomatic, high-grade (NASCET >50% [277]) carotid artery 
stenosis were enrolled. Exclusion criteria were atrial fibrillation and/or major stroke. Carotid 
plaques were sampled during CEA. Each carotid plaque was divided in two parts, one from 
which RNA was extracted and one used for histology. Control arteries were obtained from 
organ donors and included nine non-atherosclerotic iliac arteries and one aorta. 
3.2.1.2 Munich Vascular Biobank (MVB) 
MVB and its sampling protocols have been described in detail by Pelisek et al. [278]. Briefly, 
tissue samples were collected during open AAA repair or CEA. Specimens used for 
histological analyses were fixated in 4% paraformaldehyde for 48h and after that embedded in 
paraffin. For RNA analysis, fresh frozen specimens were stored at -80°C. For some of the 
patients (and if technically possible), in addition to the aneurysmal tissue sample, a proximal 
region of non-aneurysmal aortic tissue was sampled. Control aortic tissues were taken from 
organ donors. 
Patient-derived cells from AAA or atherosclerotic tissue samples were collected during open 
AAA repair or CEA and stored short-term in DMEM (Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA) at +4°C. Then, the adventitia and – if possible, the endothelium was 
removed, and the tissue was incubated at 37°C, 5% CO2 on collagen-coated Petri dishes in 
SMC Growth Medium (PELO Biotech, Planegg, Germany). Primary culture of patient-derived 
cells was used until passage 7.  
3.2.1.3 Second manifestations of ARTerial disease (SMART) 
The rationale and design of the SMART study cohort, and AAA definition and policy, have 
been described in detail before [279, 280]. Briefly, patients aged 44-80 with clinically manifest 
vascular disease or cardiovascular risk factors were enrolled at University Medical Center 
Utrecht, The Netherlands. Patients received a standardized vascular screening, including a 
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health questionnaire, laboratory assessment, and ultrasonography. Based on the power 
calculation in study IV, we aimed to include ³200 patients with ultrasonographically defined 
AAA (aortic diameter >30mm). To maximize the chance of discovery, we proceeded with 200 
patients whose AAAs were deemed clinically relevant (aortic diameter >40mm). In addition, 
from SMART, we also included 200 control patients matched for age, gender, CVD risk 
profile, and medications. For both AAA and control patients, we retrieved 200 µl of plasma, 
stored at -80°C between original sampling and final analysis. 
3.2.1.4 Stockholm AAA Biobank (StAAAB) 
The design of StAAAB has been described by Lindquist Liljeqvist et al. [281]. We received 
access to the transcriptomic profiles of patients enrolled in that study, i.e. patients undergoing 
open AAA repair. In addition, we received already extracted RNA from medial and adventitial 
tunicas of ILT-covered patient aortas (n=20), which had previously been used to establish the 
aforementioned transcriptomic profiles. For these patients, we were also provided ³200 µl of 
plasma sampled ahead of surgery. All samples were stored at -80°C between original sampling, 
extraction, and final analysis. 
3.2.1.5 Stockholm AAA screening cohort 
As part of StAAAB, during recent years, plasma from 65-year-old men from the Stockholm 
region undergoing AAA screening has been collected as recently described by Villard et al. 
[282]. Patient demographics were recorded by a structured questionnaire. Screening, plasma 
sampling, and questionnaire were all collected on the same day. AAA was defined as aortic 
diameter ³ 30mm. Subjects not diagnosed with AAA (aortic diameter <30mm) were sampled 
in a corresponding fashion and served as controls. Exclusion criteria were inadequate 
information provided in the structured questionnaire or unattainable blood sample. In total, we 
received access to 68 plasma samples (³200 µl) from AAA patients and 35 from non-AAA 
controls. The plasma samples were stored at -80°C between original sampling and final 
analysis. 
3.2.1.6 Vienna AAA cohort 
The Vienna AAA longitudinal follow-up protocol has been recently described by Eilenberg et 
al. [283]. In brief, AAA patients without indication for surgical repair were recruited through 
the Division of Vascular Surgery at Vienna General Hospital. The exclusion criteria were 
recent (<1 year) tumor and/or chemotherapy, systemic autoimmune or hematological disease, 
and organ transplantation. Patient demographics were recorded by a structured questionnaire. 
From this study population, we gained access to serum samples (³200µl) from 28 patients, as 
well as their baseline and 6-month follow-up AAA diameter measurements. The serum samples 
were stored at -80°C between original sampling and final analysis. 
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3.2.2 Animals 
3.2.2.1 C57BL/6 wildtype and Apoe-/- mice 
Apoe-/- mice were used in mouse models requiring dyslipidemic conditions. In studies II and 
III, C57BL/6J background mice were used, in study IV C57BL/6N mice were used, and in 
study I C57BL/6J mice were used for initial experiments, but C57BL/6N mice were required 
for the development of the double-knockout (Apoe-/- Miat-/-) model (described further down). 
C57BL/6J Apoe-/- mice were purchased from Taconic Biosciences (Silkeborg, Denmark). 
C57BL/6N Apoe-/- mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). 
All mice denamed wild-type in the thesis and constituent studies were on a C57BL/6J 
background and purchased from Taconic Biosciences. 
3.2.2.2 C57BL/6N Apoe-/- Miat-/- double-knockout mice 
Miat-/- mice (originally denoted Gomafu CDB1347K) on C57BL/6N background were a kind 
gift from Professor Nakagawa at RIKEN Center for Life Science Technologies, Kobe, Japan 
[284]. These Miat-/- mice were intercrossed with C57BL/6N mice creating Apoe-/- Miat-/- 
double-knockout mice. Consequently, Miat-/- mice maintained on a C57BL/6N background 
with heterogenous breeding served as single-knockout controls. 
3.2.2.3 Mouse housekeeping 
All mice were housed and experiments were performed at the animal facilities provided by the 
Comparative Medicine unit at Karolinska Institutet. The only exceptions were AngII AAA 
C57BL/6J Apoe-/- mice in study III; these experiments were performed by collaborators in 
Austria, Vienna. Animals were housed under standard conditions (temperature 22°C, humidity 
56%, 12-hour light/12-hour dark cycle). Mice were co-housed in cages enriched in accordance 
with animal welfare legislation. Mice were attended daily by the animal facility staff and had 
free access to food and water. All mice were fed chow-diet (R36; Lantmännen, Stockholm, 
Sweden). Upon experiment end, mice were euthanized through CO2 inhalation, exsanguinated 
by heart puncture, and perfused with 4°C PBS before organ harvesting.  
3.2.2.4 LDLR-/- Yucatan mini-pigs 
LDLR-/- Yucatan mini-pigs were provided by Exemplar Genetics (Coralville, IA, USA). The 
pigs were housed in animal facilities at Technical University Munich, co-housed in groups of 
2-4 under conventional hygienic conditions. Environmental enrichment was provided and 
general conditions were: temperature 19 ± 2°C; humidity 50–60%; 12-hour light/12-hour dark 
cycle. The mini-pigs received an acclimatization period of at least nine days before undergoing 
surgery. They were fed with a pelleted high-fat diet (Altromin, Lage, Germany) twice a day 
and received water ad libitum. Before anesthesia, the mini-pigs were fasted for 12 hours with 
free access to water. Blood sampling and other procedures were performed under anesthesia. 
Upon experiment end, animals were sacrificed using pentobarbital (>50mg/kg) and 40ml of 
1M KCl solution. 
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3.3 ANIMAL MODELS 
3.3.1 Mice 
3.3.1.1 Mouse anesthesia 
All experiments (including serial ultrasound measurements, if applicable) were performed 
under anesthesia. Mice were placed under 2% isoflurane anesthesia. Prior to the procedure, 
anesthesia depth was verified by toe pinch. After procedure completion, mice were left to 
recover in open enriched cages under an infra-red lamp to minimize body temperature loss. 
Mice were then observed until fully recovered from the procedure and no signs of distress were 
visible. Upon complications, mice were either provided additional analgesia or terminated, in 
accordance with the ethical permit protocols.   
3.3.1.2 Inducible carotid plaque rupture model 
For studies of plaque vulnerability and rupture, we used a modified ligation and cuff model in 
Apoe-/- mice [285, 286]. In this approach, a conical rather than symmetrical cuff is used to 
induce shear-stress more efficiently, as proposed by Kuhlmann et al. [287]. By combining this 
with prior common carotid artery ligation, plaque development and subsequent rupture can be 
induced. In contrast to the ligation and cuff model described by Sasaki et al. [164], our approach 
does not require the mice to be fed a high-fat diet [270, 285]. 
Briefly, 10-12-week-old male Apoe-/- mice are anesthetized with 2% isoflurane. Via medial 
neck incision, the right common carotid artery is dissected from surrounding connective tissue. 
Directly below carotid bifurcation, a 5-0 Vicryl (Ethicon, Bridgewater, NJ, USA) suture is used 
to partially ligate the artery. On day 28 after ligation, a cone-shaped plastic 1.7mm long cast 
consisting of two rigid halves (Promolding BV, Rijswijk, Netherlands) is placed around the 
common carotid artery, proximal to the ligation site. The internal lumen of the cuff ranges from 
300µm (proximal) to 150µm (distal). After four days, animals were sacrificed, and after PBS 
perfusion, the right common carotid artery was macroscopically inspected for signs of plaque 
rupture. 
3.3.1.3 Angiotensin II infusion AAA model 
The advantages/disadvantages and characteristics of different models of murine AAA are 
thoroughly discussed in section 1.5.2. Briefly, C57BL/6J Apoe-/- mice were placed under 
anesthesia. Osmotic minipumps releasing AngII at 1,000 ng/kg min-1 (sized 20 x 6mm) were 
implanted subcutaneously through a small dorsal flank incision. Using ultrasound (Vevo 2100, 
Visualsonics, Toronto, Canada), maximum infrarenal aortic diameter was measured under 
anesthesia at baseline, day 7, day 14 and day 28 after pump implantation. After the final 
diameter measurement, the anesthetized mice were sacrificed through heart puncture. 
3.3.1.4 Porcine pancreatic elastase perfusion AAA model 
Briefly, 10-week-old male C57BL/6J WT mice were placed under anesthesia. After careful 
dissection of the aorta from surrounding tissue, proximal and distal temporary silk ligatures 
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were placed. A microcatheter was then inserted into the aortic lumen, and the lumen was 
perfused with PPE (Sigma-Aldrich, Burlington, MA, USA) at a concentration of 2U/mL for 10 
minutes. After thorough flushing of the aorta with saline, a single knot 10-0 Prolene (Ethicon) 
suture was used to seal the catheter entry site. The abdomen was closed layer by layer with  
5-0 Vicryl (Ethicon) running sutures. 
3.3.1.5 Tissue harvesting and blood sampling 
After euthanasia through CO2 inhalation, blood was collected through heart puncture into 
EDTA containers and centrifuged at 10,000xG for 10 minutes. Plasma was transferred to new 
Eppendorf tubes and stored at -80°C. Relevant organs were snap-frozen or embedded in 
Optimal Cutting Temperature Cryomount compound (OCT, Histolab, Gothenburg, Sweden) 
and thereafter stored at -80°C. 
3.3.2 Mini-pigs 
3.3.2.1 Yucatan mini-pig LDLR-/- pancreatic elastase perfusion AAA model 
The advantages of using Yucatan mini-pigs are discussed in section 1.5.2.3. In summary, these 
animals possess physiological characteristics that can be likened to humans, with similar body 
weight, blood pressure, and heart rate. This is in contrast to most commonly used murine AAA 
models. Through this approach, the translational potential of interventional studies can be 
further enhanced. It also allows for the use of drug delivery tools with translational relevance 
for human patients, such as drug-eluting stents/balloons. 
Anesthesia, analgesia, peri- and postoperative monitoring are all thoroughly described in the 
supplemental material of study III. Prior to surgery, the baseline aortic diameter was measured. 
The porcine aorta was exposed via left lateral flank access. The aorta was clamped over 3-4 
cm. A PTA balloon (Medtronic, Minneapolis, MN, USA) was used to predilate the aorta. PPE 
(Sigma-Aldrich) was perfused at 10U/mL for 10 minutes through a blunt 5G needle. After 
flushing with heparinized saline (1000 U/L), the aortic incision was closed with a 5-0 Prolene 
suture (Ethicon) before the clamps were released. The surgical wound was closed layer-by-
layer and covered with a spray-on dressing. 
Repeated diameter measurements were performed at day 0, day 7, day 14, and day 28. Blood 
was sampled at day 0, day 7, and day 28. If applicable, on day 7, a drug-eluting balloon was 
spray coated with the therapeutic of choice and applied to the aneurysmal part of the porcine 
aorta (described in studies II and III). Animals were sacrificed on day 28 post AAA-induction. 
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3.4 KEY MOLECULAR METHODS 
Detailed methods and protocols have been thoroughly described in the published papers 
(studies I and III) / attached manuscripts (studies II and IV), and supplemental materials. 
Key methods and methodological considerations are described below. Methodological 
limitations are discussed in section 4.5. 
3.4.1 Genomics & bioinformatics 
3.4.1.1 RNA isolation and RT-qPCR 
Sample handling, RNA/protein extraction, are thoroughly described in the methods sections of 
each constituent study. RNA was extracted using manufacturer protocols, depending on 
material type, using one of the following kits: miRNeasy Micro Kit, miRNeasy Mini Kit, 
miRNeasy Advanced Serum/Plasma Kit, miRNeasy Advanced Tissue/Cells Mini Kit (all 
Qiagen, Hilden, Germany). For plasma/serum samples, cel-miR-39 was spiked in as a control 
during the extraction. The concentration of total RNA was measured using NanoDrop 2000 
spectrophotometer (Thermo Fisher Scientific). For miRNA analysis, RNA was diluted in 
RNAse-free water to a concentration of 2 ng/µl. cDNA synthesis was performed using TaqMan 
microRNA Reverse Transcription Kit (Thermo Fisher Scientific), using 10 ng of total RNA, 
with reverse transcriptase (RT) primers specific for each miRNA. For serum/plasma samples, 
RNA concentration was not measured, and 2 µl of the total elute (20 µl, extracted from 200 µl 
human or 100 µl mouse serum/plasma) was used for each miRNA RT reaction. For gene 
expression analysis, 200-1000 ng total RNA was used for cDNA synthesis using the TaqMan 
High-Capacity cDNA Transcription Kit. Expression of mRNA/miRNA was quantified using 
TaqMan FAM/VIC-labeled assays on the QuantStudio 6/7, 7900HT and StepOnePlus RT PCR 
systems (all Applied Biosystems, Thermo Fisher Scientific). Differences in gene expression 
were calculated as 2-DDCt. 
3.4.1.2 Gene expression / miRNA microarrays 
Applied Biosystems OpenArray technology was used to assay relative plasma miRNA 
expression in study IV, further explained in the methods section of the manuscript. In this 
approach, microchips containing wells coated with TaqMan probes for 758 different miRNAs 
were loaded with cDNA synthetized using a RT primer mix containing primers specific to these 
miRNAs. The OpenArray chips were cycled and processed on the QuantStudio 12K Flex 
System (Applied Biosystems). In study III, we used Affymetrix GeneChip Mouse 
Transcriptome Assay 1.0 (Thermo Fisher Scientific) to profile gene expression changes in the 
aortas of mice treated with lenvatinib. 
3.4.1.3 RNA sequencing 
In study IV, to identify potential targets of miRNA-15a-5p (miR-15a), we sequenced RNA of 
primary human aortic SMCs, harvested 48h post-transfection with miR-15a-mimic (n=3), miR-
15a-inhibitor (n=3) or scrambled control oligo (n=3). Library preparation and RNA sequencing 
were performed by a commercial vendor (Novogene UK Company Ltd, Cambridge, United 
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Kingdom). Libraries were sequenced on the Illumina NovaSeq PE150 platform (Illumina, San 
Diego, CA, USA) and >40M paired-end reads were generated for each sample. Reads were 
cleaned, mapped, aligned, and analyzed for differential expression by the commercial vendor. 
Downstream bioinformatic analyses were independently performed by the author. 
3.4.1.4 miRNA / lncRNA target prediction 
For study IV utilized available in silico miRNA target prediction data from DIANA microT-
CDS [288, 289], miRDB 6.0 [290, 291], miRWalk 3.0 [292], as well as experimentally 
validated targets from miRTarBase [293]. In study I, we looked at interactions of lncRNA and 
DNA / proteins. DNA-lncRNA interactions were predicted using LongTarget v2.1 [294]. 
Protein-lncRNA interactions were predicted using RegRNA v2.0 [295].  
3.4.1.5 Data integration and tools for data interpretation 
Microarray and RNA sequencing experiments create large amounts of data. In these 
experiments, thousands of differentially expressed genes can be identified. Many different 
bioinformatic tools have been developed to aid in converting this information into biologically 
relevant conclusions. Some examples include clustering, overrepresentation, enrichment, and 
network analyses. In the presented studies, the most common approach was analysis of gene 
enrichment/overrepresentation in known signaling pathways and in sets of genes that give rise 
to certain types of biological responses such as inflammation, apoptosis, or hypoxia. 
All data analysis was performed using R. Bioconductor is a collection of libraries for R 
pertaining to the analysis of bioinformatics data. Among the most commonly used libraries 
were limma, clusterProfiler, HTqPCR, ggplot2 [296–299]. 
3.4.2 Histology 
3.4.2.1 Tissue preparation and imaging 
Tissues used for histological analyses were either fresh frozen and embedded in OCT 
(Histolab) or formalin-fixed and paraffin-embedded (FFPE). Fresh frozen tissues were cut into 
6 µm thick (mouse carotid) or 8 µm thick (mouse aorta) sections onto positively charged 
SuperFrost Plus slides (Menzel Gläser, Braunschweig, Germany), dried and stored at -80ºC. 
Paraffin-embedded tissues were cut into 5 µm thick sections. Slides from fresh frozen tissues 
were thawed, once again dried, and fixed in 4% paraformaldehyde for 10 minutes. Basic tissue 
morphology was visualized through either hematoxylin and eosin or elastic van Gieson stains. 
Imaging was performed using either a Leica Microsystems TCS SP8 (Wetzlar, Germany) 
confocal microscope or Olympus SLIDEVIEW VS200 (Tokyo, Japan) slide scanner. 
3.4.2.2 Laser capture microdissection 
In studies of fibrotic caps in plaques, especially in study II, localized changes in gene 
expression can be ‘drowned out’ by other unaffected parts of the tissue when analyzing bulk 
gene expression of whole lesions. Therefore, a laser capture microdissection approach was used 
 
40 
to extract RNA solely from the histological areas of interest. Up to 10 consecutive slides per 
patient were micro-dissected and put into RLT buffer (Qiagen), whereafter RNA extraction 
was performed according to standard protocols. 
3.4.2.3 Immunohistochemistry / immunofluorescence 
Immunoassays were used to identify proteins in tissue sections from patients and experimental 
animals. Fresh-frozen sections were processed directly, while FFPE sections were first 
deparaffinized in xylene and rehydrated in decreasing serial ethanol dilutions. For FFPE 
sections, antigen retrieval was performed by heating in a citrate buffer. Subsequently, serum 
blocking and H2O2 blocking (only in immunohistochemistry, to quench endogenous peroxidase 
activity) were performed. Slides were incubated with primary antibody (except for negative 
control slides where this step was omitted) and thereafter with an HRP-conjugated 
(immunohistochemistry) or fluorophore-conjugated (Alexa, Thermo Fisher Scientific) 
secondary antibody (immunofluorescence). For immunohistochemistry, HRP-activity was 
visualized by incubating the slides with AEC or DAB substrate and nuclei counterstained with 
hematoxylin. For immunofluorescence, nuclear counterstaining was performed through 
incubation with DAPI.  
3.4.2.4 Fluorescent in situ hybridization (FISH) 
FISH was used to visualize genes and miRNA in tissue sections from patients and experimental 
animals. Sections were deparaffinized and rehydrated as per above (FFPE) or processed 
directly (fresh frozen). H2O2 blocking was performed, and sections were 
predigested/permeabilized using proteinase-K (in a concentration recommended by Exiqon for 
respective section type) for 10 minutes at 37ºC. The double-DIG-labelled miRNA in situ 
hybridization (ISH) probes (Exiqon, Vedbæk, Denmark) were hybridized for 2h at 30ºC below 
their manufacturer-specified melting temperature (Tm). Scrambled control probes were used as 
negative control. Stringency washes were performed in serial dilutions of saline-sodium citrate 
(SSC) buffer at room temperature. After blocking, sections were incubated with a secondary 
anti-DIG-POD (HRP) antibody (Sigma-Aldrich), after which the signal was visualized by 
incubation with an Alexa-TSA (Thermo Fisher Scientific) substrate. 
In situ hybridization of lncRNA was performed using the RNAscope Multiplex Fluorescent v2 
Assay (ACD, Bio-Techne, Minneapolis, MN, USA) according to the manufacturer’s 
instructions. The advantage of the RNAscope approach over standard FISH is that it requires 
two independent probes to hybridize to the target RNA for amplification to occur. This 
minimizes the issue of non-specific hybridization that can often be an issue with standard FISH 
protocols. RNAscope also includes a signal-amplification step, where a tree-like scaffold is 
built on top of the two specific probes, each part of the scaffold conjugated to an HRP-enzyme. 
Thereafter, the signal can be visualized by a standard fluorophore (Alexa/Opal)-TSA 
incubation, activated upon contact with HRP. 
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3.4.2.5 Multiplexing 
The FISH protocol can be combined with immunofluorescence to aid in assessing 
colocalization of lncRNA/miRNA and e.g. cell-type-specific protein markers. The standard 
FISH protocol was followed until after Alexa-TSA substrate incubation. Thereafter, 
immunofluorescence was performed, starting with the primary antibody incubation step. One 
disadvantage of this approach is that it excludes antigen retrieval in citrate buffer solution and 
instead includes a proteinase-K pre-digestion step. Due to this, certain primary antibodies may 
be incompatible with this approach due to epitope unavailability/loss. In multiplex protocols, 
extra care was taken to ensure no signal carryover between different fluorophores. For this 
reason, apart from standard negative control slides that were always included in all histological 
studies, additional single-stain negative controls were included when staining in multiplex. 
3.4.3 Cell culture 
3.4.3.1 General conditions 
Cells were cultured in incubators at 5% CO2 and atmospheric O2 levels. All experiments were 
performed under sterile conditions in laminar flow hoods. All in vitro experiments were 
performed in triplicates or more. Methods for RNA isolation are described in section 3.4.1.1. 
Protein lysates were harvested using RIPA buffer (Sigma-Aldrich) supplemented with 
phosphatase inhibitors, protease inhibitors, and EDTA and stored at -20ºC. 
Cell types used were primary aortic and carotid SMCs (Cell Applications, San Diego, CA, 
USA), HEK293 cell-line (Public Health England Culture Collections, Salisbury, United 
Kingdom), THP-1 (gift from the Vascular Surgery Unit at Karolinska Institutet), immortalized 
VSMC cell-line (Applied Biological Materials, Richmond, Canada), as well as primary patient 
cells from MVB. For primary cells, cell passages no later than passage 7 were used. 
3.4.3.2 Isolation of primary cells 
Primary mouse aortic SMCs were isolated from pooled mouse aortas and propagated in DMEM 
medium (Thermo Fisher Scientific). Primary patient carotid/aortic SMCs were isolated from 
tissue samples collected during open AAA repair or CEA. They were stored in DMEM medium 
(Thermo Fisher Scientific) short-term at 4ºC, whereafter adventitia and endothelium were 
removed and remaining tissue incubated to propagate on collagen-coated Petri dishes in SMC 
Growth Medium (PELO Biotech). 
3.4.3.3 Transfection 
In all constituent studies, transfection of ASOs or miRNA-mimics was performed to study the 
effect of gene expression changes on functional phenotypes. Transfection was performed using 
Lipofectamine RNAiMAX (Thermo Fisher Scientific). All RNA transfection experiments 
were controlled by parallel transfection of scrambled constructs of the same chemistry. All 
overexpression experiments (except for miRNA) were performed through transient 
transfection with expression plasmids, using Lipofectamine 3000 (Thermo Fisher Scientific). 
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Plasmid experiments were controlled through parallel transfection with an empty vector of the 
same backbone. 
3.4.3.4 Live-cell imaging (cell migration, proliferation, apoptosis) 
Studies of cell dynamics were performed using an automated live cell imaging system 
(IncuCyte Zoom, Sartorius, Göttingen, Germany). An image masking algorithm was trained to 
study proliferation for the particular cell type. Images were automatically taken every second 
hour, whereafter the IncuCyte Zoom software calculated confluency for each timepoint. For 
apoptosis studies, the cell culture medium was supplemented with either a Caspase 3/7 
Apoptosis reagent (Sartorius, Göttingen, Germany) in a 5 µM concentration or an Annexin V-
Alexa Fluor™ 594-conjugate (Thermo Fisher Scientific) in a 1:100 dilution. Thereafter 
apoptosis could be monitored by automated observation of the number of cells fluorescently 
labeled by the reagent. For cell migration studies, cells were plated and grown to a 90% 
confluency in IncuCyte ImageLock 96-well plates (Sartorius). The ImageLock plates have 
optically clear bottoms with physical markings allowing for a reproducible objective lock of 
the automated IncuCyte Zoom live cell imaging system. Before imaging, an identical wound 
was created in all wells using the IncuCyte WoundMaker (Sartorius). The kinetics of wound 
closure were then continuously (every second hour) monitored. 
3.4.4 RNA interactions 
Co-localization in histological tissue sections (described in section 3.4.2.5), or other 
approaches such as proximity ligation assays, can sometimes be considered indirect evidence 
of interplay between genes or proteins. However, these techniques do not prove that an actual 
interaction takes place. In our studies, we used the following methods to establish evidence of 
interaction between different molecules. 
3.4.4.1 Luciferase reporter assay 
The luciferase reporter assay can be used to establish either transcriptional (e.g. for lncRNAs) 
or post-transcriptional (e.g. for miRNAs) effects on target genes. Cells are transfected with an 
expression plasmid containing the firefly luciferase gene (Active Motif, Carlsbad, CA, USA) 
under control of a target promoter (for studying effects on transcription) or containing a target 
3’UTR region (for studying post-transcriptional mechanisms of miRNAs). 24h after 
simultaneous transfection with the ncRNA of interest, the luciferase signal can be quantified 
by lysis of the cells, the addition of a luciferase substrate, and subsequent read-out in a 
luminometric microplate reader. 
3.4.4.2 RNA immunoprecipitation 
The binding of RNA to proteins of interest can be studied through RNA immunoprecipitation. 
Briefly, upon immunoprecipitation using an antibody designed to target a specific protein, 
RNAs that bind to this protein can be expected to co-precipitate into the immunoprecipitated 
protein-enriched fraction. Observed enrichment of RNA expression in the protein-enriched 
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fraction constitutes proof that these molecules can interact. However, this does not explicitly 
imply a direct interaction, as other co-interactors might mediate in this process. 
3.5 STATISTICS 
3.5.1 Analysis of experimental data 
GraphPad Prism 9 (San Diego, CA, USA) was used to perform statistical inference on 
experimental data. Differences between two groups were primarily analyzed by a two-sample 
(Student’s) t-test, either unpaired or paired depending on the study design. Normality was 
assumed for measurements expected to follow a normal distribution (according to the central 
limit theorem) and, if needed, verified using D'Agostino-Pearson or Shapiro-Wilks normality 
tests. Q-Q plots were used to visually inspect the data normality. If a normal distribution could 
be achieved through appropriate data transformation, this approach was preferred. For 
example, gene expression data was compared using the log2 expression values and then 
transformed into fold-change for presentation purposes. Otherwise, the nonparametric Mann-
Whitney U test was chosen. Equal variances were similarity first hypothetically evaluated, 
inspected on a homoscedasticity plot, and thereafter tested using the F-test of equality of 
variances. If the variance was different between groups, Welch’s t-test was used. Welch’s t-
test was also preferred if sample sizes were unequal. Statistical comparison of frequencies was 
performed using the chi-square test. Two-sided p<0.05 was considered statistically significant. 
One-sided p<0.05 was considered significant when there was a clear prior hypothesis on the 
direction of change, e.g. in validatory experiments. Throughout this thesis and its constituent 
studies, significance levels are depicted as follows: * = p<0.05, ** = p<0.01, *** = p<0.001, 
**** = p<0.0001. 
When comparing more than two groups, an analysis of variance (ANOVA) approach was used, 
in either one- or two-way design, depending on the number of analyzed factors. In addition, if 
a subject was assayed multiple times over time, a repeated-measures design was used. 
Normality and variance assumptions were assessed visually (through Q-Q and 
homoscedasticity plots). If significant divergence was observed, Shapiro-Wilk’s and Levene’s 
tests were additionally performed. Post hoc multiple comparisons of ANOVA analyses were 
performed using the Tukey method, or using Fisher’s LSD test with subsequent Šidák (Dunn-
Šidák) or Holm-Šidák corrections. 
Linear regression was used to study the association between continuous variables, and a t-test 
was used to assess its significance. Pearson correlation coefficient (r) was calculated to quantify 
the degree of correlation. 
3.5.2 Analysis of transcriptomics data 
All analyses of data stemming from high-throughput transcriptomics experiments (microarrays 
and RNA sequencing) were performed using R and selected Bioconductor libraries. 
Differential expression analysis of microarray data was performed using limma or limma-
dependent libraries. Differential expression analysis of RNA sequencing data was performed 
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using DESeq2 or edgeR. Overrepresentation analyses (ORA) and gene set enrichment analyses 
(GSEA) were performed using clusterProfiler. Resulting p-values from all above-described 
approaches (differential expression, ORA, GSEA) were adjusted for false discovery rate using 
the Benjamini-Hochberg approach. Specific approaches, including data normalization 
strategies, are more thoroughly explained in each constituent study. 
3.6 ETHICAL CONSIDERATIONS 
To allow evaluation of our research hypotheses, there is an inherent need for use of animal 
models, for all of which (murine AngII / PPE models, Yucatan mini-pig PPE models) we 
currently hold updated ethical permits. Nonetheless, when designing and performing animal 
experiments, it is important that Russell & Burch’s 3R [300, 301] are taken into consideration. 
For the diseases studied, animal experiments cannot be entirely replaced by ex vivo or in vitro 
approaches. The compounds being evaluated have not yet been tried in humans, and it would 
therefore be unethical to progress with such unless effects have been thoroughly verified in 
animal studies. Reduction is performed through careful analyses of human AAA tissues and/or 
blood samples, to only perform animal experiments deemed relevant to human vascular 
disease. In addition, calculations regarding the sample size of animal experiments are based on 
previous experience and complemented by power analyses to ensure that the smallest possible 
number of animals are used while still being able to reach statistically sound conclusions. 
Refinement is performed through Karolinska Institutet established protocols, including careful 
monitoring of animals’ well-being by researchers in our group and animal facility staff (at least 
once daily). All models are based on the latest knowledge within the field. To further minimize 
suffering, all invasive procedures are performed under general anesthesia, and the animals 
receive pre-procedure analgesics routinely and during 24-48h post-procedure or later if 
required (described in more detail in previous sections).  
When working with external biobanks to access patient samples or tissues, care was taken to 
ensure that all ethical permits were in check and that there was a proper protocol for patient 
consent, in line with the Declaration of Helsinki [302]. 
Upon publication, data from bioinformatic experiments will be made available in public 
repositories to ensure transparency and maximize the impact of public funds and effort put into 
our work. All constituent studies have been, or will be, published in open-access journals to 
maximize data availability. 
The studies we perform are explorative and will not necessarily instantly contribute to changes 
in clinical practice. Nonetheless, through the use of novel, more relevant models, we aim to 
facilitate the translation of our research findings into clinical trials and in the long term into 
clinical practice. Regardless of whether this turns out successful, our findings will contribute 
to a better understanding of the diseases studied and thus facilitate continued research into the 
pathologies in question.
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4 RESULTS AND DISCUSSION 
4.1 SUMMARY OF KEY RESULTS 
Results have been independently reported and discussed in the published papers (studies I and 
III) / attached manuscripts (studies II and IV). Key findings of each of the studies are 
summarized below and are thereafter discussed through the lens of vascular disease and 
important aspects of pathogenic processes that characterize atherosclerosis and/or AAA. 
4.1.1 Study I 
Expression of lncRNA MIAT is increased in vulnerable carotid plaques from patients. In vitro, 
MIAT expression can be induced in VSMCs through stimulation with oxLDL and 
lipoprotein(a). We show MIAT to participate in phenotypic switching of VSMCs. We suggest 
the following mechanisms for its role: a) through interaction with the Klf4-promoter and 
induction of ELK1-phosphorylation, MIAT promotes de-differentiation of VSMCs into more 
inflammatory macrophage-like phenotypes; b) through activation of the EGR1-ELK1-ERK 
pathway, MIAT promotes proliferation and survival of VSMCs. In addition, we show that MIAT 
participates in the regulation of macrophage-specific processes: a) it facilitates the activation 
and nuclear translocation of NF-κB; b) it promotes expression of transporters (CD36, SRA) 
involved in oxLDL uptake through a yet unknown mechanism. Overall, MIAT seems to drive 
key processes in the development of atherosclerotic plaques and their progression towards 
more advanced stages. However, it does also promote the stability of very advanced plaques 
through its positive effects on VSMC survival and therefore fibrous cap thickness. Lastly, we 
were able to observe the presence of the above-described effects in LDLR-/- Yucatan mini-pigs, 
increasing their translational feasibility. 
4.1.2 Study II 
In laser-capture micro-dissected fibrous caps of patient carotid plaques, we found FGF2 to be 
down-regulated and its natural antisense transcript NUDT6 up-regulated in fibrous caps of 
unstable (cap thickness ≤ 200 µm) vs stable (cap thickness > 200 µm) lesions. This was also 
true in aortic tissues from AAA patients compared to organ donor controls. Stimulation by 
either oxLDL or AngII led to in vitro increase of NUDT6 in human carotid or aortic VSMCs 
respectively. In vitro overexpression of NUDT6 led to a repression of FGF2 in human VSMCs 
and consequently decreased their proliferation and increased apoptosis. In the mouse model of 
plaque rupture by carotid ligation and cuff placement, in vivo inhibition of Nudt6 led to a 
decreased plaque rupture rate. In both the PPE perfusion and AngII infusion mouse models of 
AAA, Nudt6 inhibition limited aneurysm growth. We also evaluated NUDT6 inhibition in our 
translational porcine AAA model in LDLR-/- Yucatan mini-pig model receiving PPE perfusion. 
While we could not observe any significant effects on AAA diameter, analysis of aortic tissues 
showed successful inhibition of NUDT6, a consequential increase of FGF2 and MYH11 – 
suggesting increased VSMC survival. In line with this, histological analysis of porcine tissues 
showed more FGF2-positive and SMA-positive cells in NUDT6 inhibited animals. 
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4.1.3 Study III 
We evaluated lenvatinib, a multi-kinase inhibitor known to inhibit VEGFR2, as a potential 
therapeutic agent for patients with AAA. In both PPE and AngII models of murine AAA, 
treatment with lenvatinib led to less AAA diameter growth. In addition, local (as opposed to 
systemic) delivery of lenvatinib through surgical reintervention yielded similar results. To 
ensure translational feasibility, we also employed our LDLR-/- Yucatan mini-pig PPE AAA 
model, where DEB-mediated local delivery of lenvatinib successfully halted AAA progression. 
Studies using microarray technology, immuno-histomorphological analysis of in vivo 
experiments, and cell culture models (including primary patient-derived cells) indicated that 
lenvatinib keeps VSMCs in their contractile phenotype and thus restores vessel wall integrity 
upon aneurysm induction.   
4.1.4 Study IV 
We identified miR-15a as up-regulated in plasma from patients with AAA compared to 
controls. Its expression was similarly up-regulated in plasma of PPE and AngII murine AAA 
model mice and aneurysmatic aortic tissues from patients. Through analysis of material from 
three additional independent AAA patient cohorts, we were able to: a) confirm that miR-15a 
levels are higher in plasma of patients with large aneurysms vs control; b) observe that levels 
of miR-15a in tunica media correlate with AAA diameter; c) observe that levels of miR-15a in 
plasma and serum correlate with AAA diameter. Through in silico miRNA target prediction as 
well as RNA sequencing of human aortic VSMCs transfected with miR-15a modulators, we 
suggest a role of miR-15a in the modulation of VSMCs towards a more inflammatory 
phenotype. Lastly, through systemic delivery of miR-15a inhibitors, we were able to limit AAA 
diameter growth in the murine PPE perfusion model of AAA. 
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Table 3. A brief overview of study results. 
Study 
Target & affected 
pathways 
Observed effect on 
VSMC phenotype 
Experimental 
modulation 
in vitro 
Experimental 
modulation 
in vivo (mice) 
Experimental 
modulation 
in vivo (mini-pigs*) 
I 
MIAT 
↑ KLF4  
↑ NF-kB 
↑ ERK-ELK1-
EGR1 
Mediates VSMC 
trans-differentiation 
into inflammatory 
macrophage-like 
phenotype 
KD in hCtSMCs: 
↓ proliferation 
↑ apoptosis 
KD in MP: 
↓ oxLDL uptake 
Inhibition 
(GapmeR) reduces 
atherogenesis, 
increases  
experimental 
plaque vulnerability 
Not modulated 
MIAT, KLF4, EGR1, 
and ELK1 all 
decreased in mini-
pigs with more severe 
lesions. 
II 
NUDT6 
↓ FGF2 
Opposed effect to 
FGF2, which is 
known to promote 
de-differentiation of 
VSMCs into an 
activated, 
proliferative 
phenotype 
OE in hCtSMCs: 
↓ proliferation 
↑ apoptosis 
↓ migration 
OE in 
hAoSMCs: 
↓ proliferation 
↑ apoptosis 
↓ migration 
Knockdown 
(GapmeR) 
Plaque rupture: 
↓ rupture rate 
 
PPE: 
↓ diameter 
↑ 𝛼-SMA content 
 
AngII: 
↓ diameter 
↑ 𝛼-SMA content 
↑ preservation of 
elastic lamellae 
Knockdown 
(GapmeR) 
 
Aorta: 
↑ 𝛼-SMA content 
↑ preservation of 
elastic lamellae 
III 
Inhibition of 
VEGF-signaling 
(VEGFR2) via 
lenvatinib 
↓ VEGF 
↓ ERK 
↑ MYH11 
Promotes a 
contractile 
phenotype through 
several potential 
mechanisms 
hAoSMCs: 
↓ proliferation 
↓ apoptosis 
↓ migration 
 
AAA patient-
derived cells: 
↓ proliferation 
↓ migration 
↑ contractility 
↑ contractile 
gene expression 
Systemic 
treatment 
PPE: 
↓ diameter 
↑ SMC contractility 
 
AngII: 
↓ diameter 
Systemic and 
targeted (DEB) 
delivery 
↓ diameter 
↑ SMC contractility 
IV 
miR-15a-5p 
↑ broad network 
of inflammatory 
genes 
No established 
phenotype 
 
Pro-inflammatory 
hAoSMCs: 
↓ proliferation 
↑ apoptosis 
(literature) 
Knockdown 
(antagomiR) 
PPE: 
↓ diameter 
↑ 𝛼-SMA content 
 
 
– 
Abbreviations: KD – knock-down, OE – over-expression, hCtSMCs – human carotid smooth muscle cells, hAoSMCs – human 
aortics smooth muscle cells, MP – macrophages, PPE – porcine pancreatic elastase murine AAA model, AngII – angiotensin II 
infusion murine AAA model, DEB – drug-eluting balloon, (V)SMC – (vascular) smooth muscle cell. * – LDLR-/- Yucatan mini-pig 
porcine pancreatic elastase AAA model. 
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4.2 KEY ROLES OF VSMCS IN VASCULAR DISEASE 
During the last decade, extensive efforts have been made to closer understand the role of 
VSMCs as involved in key processes present in vascular disease that previously had been 
attributed to other cell types [56]. Several key publications have been able to more or less 
confirm what many researchers had long suspected – that the many key processes in 
atherogenesis and atherosclerotic plaque progression (but also in AAA) can in different ways 
be attributed to VSMC behavior [303]. This is mediated by the ability of VSMCs to de-
differentiate and transdifferentiate into functionally distinct phenotypes. This spectacular 
plasticity should be seen as a key ‘feature’ rather than a weakness, especially given that 
contractile differentiation of VSMCs is not definitive. Much evidence points towards this 
plasticity being important in the maintenance of vascular wall homeostasis and its ability to 
adapt to changing, and sometimes pathological, conditions. 
In study I, we discovered that the lncRNA MIAT could positively regulate KLF4 on a 
transcriptional level, through a lncRNA-DNA interaction with the KLF4 promoter. In silico 
analysis revealed potential binding sites for Miat/MIAT at the Klf4/KLF4-promoter (Figure 8). 
In human VSMCs, oxLDL-induced MIAT expression led to increased KLF4-promoter activity 
(Figure 9) and subsequently increased nuclear levels of KLF4 (Figure 10). Plasmid-based 
overexpression of Miat in murine VSMCs led to a similar increase in Klf4-promoter activity 
(Figure 9). 
 
Figure 8. Interaction of Miat/MIAT with Klf4/KLF4 promoter as predicted by LongTarget v2.1. Peaks indicate predicted 
binding sites of Miat/MIAT within Klf4/KLF4 promoter region. Figure 6D in study I. 
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Figure 9. Left: Luciferase reporter assay with human KLF4 promoter on oxLDL stimulation / MIAT knock-down (KD) 
in human carotid SMCs. Right: Luciferase reporter assay with murine Klf4 promoter (containing Miat predicted binding 
sites; Klf4 promoter_Miat) or promoter flanking regions (harboring no predicted Miat binding sites; ctrl) in mouse aortic 
SMCs upon Miatoverexpression (pCAG-Miat). Figures 6E,F from study I. 
 
 
 
Figure 10. Left: Immunostaining of KLF4 in human carotid SMCs stimulated with oxLDL and with or without MIAT 
siRNA mediated knock-down. Right: fluorescence quantification. Figure 6C from study I. 
KLF4 is a master regulator of VSMC phenotypic switching [68] through its negative role on 
MYOCD/SRF-mediated transcriptional control of contractile genes. Increased KLF4 
expression has been implicated in trans-differentiation of contractile VSMCs into macrophage-
like phenotypes [71]. In line with this, upon increased MIAT expression after oxLDL 
stimulation of human VSMCs (Figure 11), we observed a sharp decrease in expression of 
contractile markers ACTA2, TAGLN, MYH11, and sharp increases of macrophage markers 
CD68, LGALS3 (Figure 11). This correlated to increases in expression of not only KLF4, but 
also ELK1 and HDAC2 (Figure 11), both of which are known to interact with the KLF4-
MYOCD-SRF axis to induce contractile phenotype loss of VSMCs. Through further in silico 
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analysis, we identified potential lncRNA-protein interactions with ELK1 and EGR1, both parts 
of the ERK/MAPK-ELK1-EGR1 pathway. We were able to show that MIAT co-precipitated 
during immunoprecipitation with anti-ELK1 antibodies and nuclear levels of p-ELK1 were 
decreased upon MIAT knockdown in human VSMCs. 
 
Figure 11. Left: Expression of SMC, phagocytosis and/or macrophage markers in human carotid SMCs stimulated with 
oxLDL, with or without MIAT knockdown (KD). Right: Expression of MIAT, transcription factor KLF4 and its 
coeffectors ELK1 and HDAC2 in human carotid SMCs stimulated with oxLDL and with or without MIAT KD. 
Figures 6A,B from study I. 
In study II we evaluated the lncRNA NUDT6, a NAT of FGF2. Increased expression of 
NUDT6 leads to repressed levels of FGF2 and thus also FGF2-mediated signaling. FGF2 is a 
growth factor implicated in the de-differentiation of VSMCs into a proliferative phenotype 
[304]. One mechanism for this effect of FGF2 is inhibition of TGF-b [305] through a let-7 
miRNA-dependent mechanism [306, 307]. TGF-b-signaling plays a crucial role in the 
maintenance of VSMC contractile phenotype, and its loss leads to their de-differentiation [308]. 
TGF-b-signaling is reduced in unstable atherosclerotic plaques and has commonly been 
described as atheroprotective and a key modulator of vascular repair [309–311]. However, the 
overall role of TGF-b in vascular disease is complex and elusive, and its beneficial roles are 
considered to be context-dependent [309]. In AAA, several studies have shown TGF-b-
inhibition to exacerbate experimental murine AAAs [312, 313]. If the effects of FGF2 were to 
be dependent on its inhibition of TGF-b-signaling, one would therefore likely expect FGF2 to 
yield similar results. On the contrary, treatment with FGF2 has been shown to limit the 
progression of experimental AAAs [314, 315]. In line with this, in study II, we were able to 
show that inhibition of Nudt6 and thus resulting Fgf2 increase lowered experimental plaque 
rupture rates and limited experimental AAA progression in mice (Figure 12). Therefore, other 
mechanisms are likely to contribute to these effects. 
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Figure 12. Left: Systemic Anti-Nudt6 GapmeR treatment of Apoe-/- mice (n=20) significantly reduced plaque rupture in the 
inducible plaque rupture model compared to control (scramble-control treated) animals (n=19). Middle: In the angiotensin 
II model, local anti-Nudt6 treatment (n=8) via ultrasound targeted microbubble destruction led to significantly lower 
abdominal aortic diameter and reduced growth compared to control treatment (n=13). Right: Systemic anti-Nudt6 treatment 
(n=4) in the porcine pancreatic elastase mouse model significantly reduced abdominal aortic diameter and growth rate 
compared to control treatment (n=5). Mean+SEM. Data was analysed with using multiple t-tests. 
Figures 3A,C,E from study II. 
The aforementioned studies [314, 315] characterized the effects of FGF2 treatment to be 
mediated through its mitogenic properties, resulting in increased proliferation, survival of 
VSMCs, as well as an overall increased VSMC content. Kawai et al. [315] also reported 
sharply increased contractility of harvested aneurysmal aortas in animals treated with FGF2. 
This suggests that the protective effect of FGF2 is at least in part connected to its positive effect 
on the maintenance of VSMC contractile phenotype in experimental AAAs. In line with this, 
our in vivo experiments with NUDT6 modulation in different animal models showed increases 
in VSMC content (Figure 13). In vitro, human VSMCs overexpressing NUDT6 grew slower 
and displayed increased apoptotic activity (not shown; figure 4G-H in study II). 
 
Figure 13. 𝛼-SMA immunohistochemical staining in three different murine models of cardiovascular diseases show 
restoration after anti-Nudt6 GapmeR administration. Abbreviations: L – lumen; PPE – Porcine pancreatic elastase perfusion 
mouse AAA model; Angiotensin II – Angiotensin II infusion mouse AAA model; Carotid Plaque – mouse inducible carotid 
plaque rupture model; Mini-pig PPE – Porcine pancreatic elastase perfusion Yucatan mini-pig AAA model.  Figures 6A, 
S2B from study II. 
VEGF-signaling has also been implicated in the regulation of VSMC phenotype. A study by 
Liao et al. described the ability of VEGF to negatively regulate MYOCD-SRF activity through 
its induction of JAK-STAT3 signaling [316]. VEGF is otherwise known to be a key mediator 
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of hypoxia-induced angiogenesis [317]. In addition, it has been described to respond to other 
conditions present in vascular disease, e.g. increased levels of MCP-1 [318], a cytokine 
otherwise mainly known to be involved in the recruitment of monocytes into atherosclerotic 
lesions, and also expressed by macrophage-like VSMCs. Interestingly, JAK-STAT3 signaling 
has in turn been described to mediate IL-6 induced MCP-1 production by VSMCs [319], which 
might implicate certain feed-forward activity under atherosclerotic, inflammatory conditions. 
In study III, we showed that experimental murine and porcine AAA model animals receiving 
lenvatinib, a potent VEGFR2 inhibitor [275], had smaller AAA diameters and increased 
expression of contractile VSMCs markers (Figure 14).  
 
Figure 14. Left: Murine PPE aorta stained for a-SMA, MYH11, CD31. Right: Lenvatinib treated murine PPE aorta stained 
for a-SMA, MYH11, CD31. The overview images were stained using hematoxylin and eosin. Figures 1D,E from study III. 
Upon treatment with lenvatinib, AAA-patient-derived VSMCs, showed enhanced contractility 
and had a higher expression of MYOCD and contractility markers (Figure 15). This effect 
could be mediated through the aforementioned VEGF-JAK-STAT3-axis, but when looking for 
potential other pathways that lenvatinib could be affecting, we noted a decrease in 
phosphorylation of ERK1-2 upon lenvatinib treatment in patient cells. ERK-signaling has the 
potential to inhibit MYOCD through several mechanisms. It can phosphorylate ELK1, which 
then competes with MYOCD for the same binding site on SRF [69], but has also been described 
to phosphorylate MYOCD, negatively affecting its ability to regulate transcription [320]. 
In study IV, we observed that increased miR-15a, which we identified to be a circulating 
biomarker of AAA, also seems to be involved in AAA pathogenesis and has the ability to affect 
the VSMC phenotype in vitro and in vivo. Through an established inhibitory effect on 
CDKN2B, its increased expression negatively affects VSMC viability in vitro [321]. However, 
we did not believe that this was the sole action mechanism of miR-15a, as miRNAs in general 
tend to have many gene targets and can assert regulatory roles on whole networks of genes 
[322, 323]. In an unbiased approach, we performed RNA sequencing-based gene expression 
profiling of miR-15a modulated (mimic and inhibitor) aortic VSMCs. By connecting this with 
previously published gene expression data of AAA patients, we were able to identify a large 
number of potential disease-relevant targets of miR-15a. However, perhaps most importantly, 
gene-set enrichment analysis revealed that VSMCs overexpressing miR-15a were of a more 
inflammatory phenotype (Figure 16) and experimental inhibition of miR-15a in the murine 
PPE model of AAA augmented aneurysm growth (Figure 17). 
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Figure 15. Left: Representative images of collagen matrices from the collagen contractility assay after treatment with 
lenvatinib in patient AAA derived VSMCs. Right: Gene expression at the 24h time-point of the contractility assay. 
Figure S9C,D from study III. 
 
 
 
Figure 16. Left: Ridge plot of GSEA analysis results using MSigDB-H (hallmark) gene-sets. Right: Ridge plot of GSEA 
analysis results in manually selected DisGeNET gene-sets of relevant diseases. Both based on differential gene expression 
from RNA sequencing of human aortic smooth muscle cells transfected with miR-15a-mimic. Figures 5A,E from study IV. 
 
 
 
Figure 17. Left: Time-course of relative change in aortic diameter in PPE model mice treated with miR-15a inhibitor (anti-
miR15; n=4) or scrambled control inhibitor (controls; n=5). Right: Time-course of relative change in aortic diameter in 
AngII model mice treated with miR-15a inhibitor (anti-miR15; n=7) or scrambled control inhibitor (controls; n=7). Mean ± 
SEM. Figures 3A,B  from study IV. 
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There is no doubt that phenotypic polarization of VSMCs plays major roles in vascular 
pathologies. Our studies show that while maintenance of a certain (primarily contractile) 
phenotype can be beneficial, equally important is the ability of SMCs to de-differentiate into 
phenotypes that can stabilize late-stage plaques and AAAs. In the past decade, the regulatory 
roles of ncRNA on these processes have been greatly elucidated, contributing to a deeper 
understanding of VSMC phenotypic regulations in response to different conditions/stimuli.  
4.3 TREATMENT OF VASCULAR DISEASE 
Given the immense complexity of the cardiovascular system, in the era of personalized 
medicine, many are starting to realize that one-fit-for-all approaches are associated with 
limitations. In the past decades, we have learned that vascular diseases such as atherosclerosis 
and AAA more resemble cascades of interconnected pathological events rather than one-
dimensional pathologies. With this comes the realization that regulation of specific disease-
relevant processes might be beneficial at a certain point of the pathological process but highly 
detrimental at later stages. 
In study I, we discovered that MIAT regulates KLF4-signaling and the ERK1-ELK1-EGR1-
axis to promote a more proliferative, de-differentiated VSMC phenotype characterized by 
lower expression of contractile markers and drive them towards more macrophage-like 
phenotypes. It also affects NF-κB signaling, promoting the activation of pro-inflammatory 
macrophages. In vivo, in early disease stages, beneficial effects of Miat-inhibition on 
atherosclerotic plaque development were observed in mice (Figure 18). Given the similar 
dynamics of MIAT expression during porcine plaque development, it appears likely that a 
similar mechanism was present in our LDLR-/- Yucatan mini-pig model of atherosclerosis. 
However, when established, plaques of Miat-deficient mice were more likely to rupture 
(Figure 18). This further underlines the fact that vastly different therapeutic approaches might 
be required at various stages of vascular disease. 
 
Figure 18. Left: Expression of Miat in the mouse inducible plaque rupture model. Middle: Plaque development (%) the 
inducible plaque rupture model in Apoe–/–Miat–/– versus Apoe–/–Miat+/+ mice. Right: Rupture rate (%) in the inducible plaque 
rupture model comparing Apoe–/–Miat–/– versus Apoe–/– (Miat wildtype) controls. Figures 2B, 7F,G from study I. 
 
 
 55 
In study II, we studied the role of NAT NUDT6, an anti-sense partner of FGF2. We observed 
up-regulation of FGF2 by the way of NUDT6 inhibition in vivo and in vitro. FGF2 possesses 
pro-mitogenic properties, and mice receiving NUDT6-inhibitors had reduced rupture plaque 
rupture rates and smaller AAA diameters (Figure 12). FGF2 is also able to induce the MEK-
ERK1/2 cascade and inhibit TGF-b. Both of these effects could be expected to promote a more 
de-differentiated, less contractile VSMC phenotype.  
In study III, VEGFR2-inhibition, through treatment with lenvatinib, augmented aneurysm 
development in both murine and porcine AAA models (Figure 19) and contributed to the 
rescue of contractile gene expression otherwise down-regulated in these models (Figures 
14,19). The treatment also reduced the proliferation of VSMCs, also characteristic for a more 
differentiated, quiescent phenotype. 
 
Figure 19. Top-left: Ultrasound measurements of aortic diameter of PPE mice locally treated with PBS (n=3), lenvatinib 
(n=5) or untreated/sham-reoperated (n=11). Bottom-left: Ultrasound measurements of aortic diameter of PPE LDLR-/- 
Yucatan mini-pigs treated with lenvatinib-coated drug-eluting balloon (DEB; n=4) or untreated (n=7). Right: Histological 
stains (hematoxylin and eosin, anti-MYH11 immunostain) of the PPE LDLR-/- Yucatan mini-pig aortas treated as above. 
Substantial MYH11 restoration can be observed upon local lenvatinib treatment. Figures 2B, 5B,C from study III. 
Having slightly opposing roles on VSMC phenotypic polarization, the experimental treatment 
approaches in studies I, II, and III could therefore perhaps be perceived as contradictory, and 
the fact that all could achieve experimental success somewhat perplexing. However, given that 
we could successfully reproduce these approaches across several different animal models (and 
species), we believe them to be complementary. We argue that they are likely to be beneficial 
to the studied diseases at various stages and could be useful depending on the underlying 
disease phenotype and/or at different time points.  
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Given the fact that the experimental treatments are unlikely to be universally beneficial, and 
very likely to be harmful to other organs than the vasculature, methods of precise and tailored 
delivery are essential. For example, the mitogenic activity of FGF2, while protective in 
experimental late-stage atherosclerotic plaques and AAAs, is clearly detrimental in many other 
tissues. It has been described to promote cardiac hypertrophy and fibrosis [324–326] and 
several different cancers [327, 328]. The same can be said for lenvatinib, which would not 
constitute a plausible treatment for AAA through systemic delivery, due to associated severe 
adverse effects [329]. In studies II and III, we successfully employed different strategies for 
localized delivery of both traditional therapeutics (lenvatinib), but also anti-sense 
oligonucleotides (anti-NUDT6 GapmeR). The fact that we could do so in more human-like 
models (Yucatan LDLR-/- mini-pigs) lends the approaches further translational credibility. 
Non-coding RNA-based therapeutics, especially NATs and miRNAs, possess certain key 
advantages over other therapeutic mechanisms. Beneficial/harmful effects of different proteins 
(e.g. growth factors, receptors) on a plethora of diseases and conditions have been described. 
Inhibition of protein targets can be achieved through a variety of drugs. Monoclonal antibodies 
possess a highly selective affinity for a specific target. However, one drawback is that their 
target needs to be on the cell surface, and they can therefore not target intracellular proteins. 
Delivery of ncRNA therapeutics can be delivered into target cells through multiple 
mechanisms, some of which are explored in studies II and III. In addition, compared to protein 
inhibition, achieving up-regulation of target proteins is more complex, and many such targets 
have long been considered ‘undruggable’. However, given that ncRNAs can be targeted and 
inhibited by ASOs, their mRNA targets can in this way be de-repressed. An example of such 
an approach is presented through study II, where expression of FGF2 is increased in the tissue 
of choice.  
4.4 DIAGNOSIS AND MANAGEMENT OF AAA 
While potentially lethal, AAAs develop and progress silently, a significant challenge in 
diagnosing them [330]. This makes it a disease suitable for screening, and several studies have 
shown one-time ultrasound screening to be beneficial for men aged 65 years or older [331, 
332]. However, the evidence for screening is most substantial for patients who are, or have 
been, cigarette smokers, and the screening benefit of non-smokers is not as clear-cut. According 
to a recent WHO report [333], globally, tobacco use has decreased by roughly a third during 
the past 20 years, a trend that is expected to continue. Already today, the prevalence of smoking 
in Sweden is much lower, especially in the younger population [334]. This is likely one of the 
reasons why AAA prevalence in Sweden is lower than the reported prevalence worldwide. 
Nonetheless, the Swedish screening program of all men at the time they turn 65-years has so 
far been shown to be a cost-effective measure [130]. However, given the changing 
demographics and tobacco smoking patterns, this may well not be the case in the future. 
Screening for female AAA, less prevalent [122–124] but also more lethal, is currently not 
recommended [208, 332]. Rupture risk of female AAAs has also been shown to be harder to 
predict, and a larger percentage of small AAA rupture than in men [335]. Currently, most of 
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the risk-stratification and decision on which patients benefit from AAA surgery (either open or 
endovascular), aside from patients’ overall health status, is solely based on AAA diameter. The 
development of novel tools to better approximate risks involved in managing each individual 
patient, as well as novel tools to diagnose AAAs, would undoubtedly be of value. 
In study IV, we performed a discovery study looking for miRNA biomarkers in plasma from 
a large AAA patient cohort, identifying miR-15a as a potential disease biomarker. We were 
not only able to confirm the findings in other patient cohorts but saw that they also correlated 
to aneurysm diameter (Figure 20). Through treatment with miR-15a-inhibitors in vivo, we 
could limit experimental AAA growth in the murine PPE model (Figure 17). Previous studies 
on the role of miRNAs as potential AAA disease biomarkers have been performed, but thus far 
these studies have been largely underpowered and correlative. By showing that miR-15a is 
causally involved in AAA pathology, it is not only a potential biomarker but also a tool to better 
understand factors involved in AAA disease development and/or progression.  
 
Figure 20. Left: Expression of miR-15a in plasma of AAA patients (Stockholm AAA screening cohort; n=68 for AAA of 
which n=34 for AAA ≥40mm and n=34 for AAA ≤39mm) and matched controls (n=35). Middle: Correlation of plasma 
miR-15a in AAA patients (Stockholm AAA screening cohort; n=68) and their AAA diameter (AAAd). Right: Correlation 
of serum miR-15a in AAA patients (Vienna AAA cohort; n=28) and their AAAd. Figures 2D,E,G from study IV. 
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4.5 LIMITATIONS AND METHODOLOGICAL CONSIDERATIONS 
4.5.1 Patient material 
Hypotheses of studies I, II and IV have been constructed on analyses of collected patient 
material. For studies of atherosclerotic lesions, samples from patients undergoing CEA were 
collected. During the procedure, the vessel is opened, and the intimal plaque is dissected from 
the surrounding tissue, after which the remainder of the vessel wall is left intact. Therefore, 
only the innermost parts (if any) of the medial layer will be extracted and available for analysis. 
In addition, control tissues often stem from non-atherosclerotic arteries in other regions (in our 
studies, iliac arteries), collected during other vascular procedures or from organ donors. On top 
of this, even if a healthy control specimen were to be collected, it would not be possible to 
divide the layers in a CEA-like fashion, other than perhaps by removal of the adventitial layer. 
When comparing patient CEA samples to control tissues, it is therefore important to be mindful 
of the differences in overall tissue composition. For example, due to the extensive presence of 
VSMCs and VSMC-like cells in the intima-located atherosclerotic lesion, it is feasible to 
assume that these cells will constitute a significant fraction of all VSMCs in patient tissues and 
a much smaller fraction in control tissues. However, if one aims to understand the mechanism 
driving the activation of these ‘activated’ lesion VSMCs, then this approach is still likely to 
point in the right direction. 
On the other hand, one would also expect some of these phenotypic changes to be important to 
the vascular homeostasis and VSMCs’ ability to correctly respond to different stimuli. Some 
of the observed transcriptomic/proteomic changes are therefore likely to be beneficial. This 
question can hopefully better be answered by comparing stable and unstable plaques, and even 
more so if looking specifically at certain regions of interest, such as the fibrous cap. 
Many of the above points can also be extrapolated onto AAA samples. Control samples most 
commonly stem from the aortas of e.g. organ donors. For understandable reasons, the organ 
donor population is often healthier and, most importantly, much younger on average. As age is 
one of the biggest risk factors of AAA, this is certainly a problem to be aware of. To aid this, 
through the MVB, we have recently started collecting aortic tissue from non-dilated and dilated 
parts of aortas from the same patient, whenever possible. This type of paired material has been 
used for analyses in studies II and IV. 
The same problem applies to commercially available cell cultures created from aortic tissues 
of organ donors. Manufacturers either do not discriminate between cells from abdominal or 
thoracic aorta, or more commonly, only provide cells collected from the thoracic regions. 
During our studies, we have not been able to purchase explicitly abdominal primary cell 
cultures commercially. Given that these two regions of the aorta have different embryonic 
origins, care must be taken when drawing conclusions from in vitro studies on AAA-related 
mechanisms performed on thoracic primary SMC cultures. In study III, in which primary 
patient cells were isolated, we did often observe different responses to pathological stimuli than 
in commercially purchased primary cell cultures. 
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4.5.2 Animal models 
The advantages and disadvantages of the different animal models are briefly discussed in 
section 1.5.2. While all aspects of the human disease are hard to mimic, translational research 
would not be possible without the use of animals. Our group has developed a modified plaque 
rupture model, which we believe gives us a closer understanding of mechanisms governing 
plaque stability and rupture. In studies of AAA pathogenesis, we believe that the AngII and 
PPE models, while both carrying significant limitations, can answer different questions about 
the effects of different mechanisms or treatments on disease phenotypes. The described 
transgenic mini-pig model (LDLR-/- Yucatan mini-pigs), with more human-like physiology, 
adds an additional dimension to these studies. A further limitation of animal models is that the 
disease time course is profoundly accelerated, especially as both atherosclerosis and AAA 
develop slowly over time in humans. In contrast to human disease, the model atherosclerotic 
plaques do not become as advanced and complex. There are also apparent differences in, 
especially murine, coagulation and immune systems, preventing observations of disease-
specific outcomes. 
Nonetheless, it needs to be acknowledged that a lot of knowledge regarding novel concepts of 
vascular disease has been built based on animal (primarily mouse) studies. Additional efforts 
are required to ensure that these knowledge gains can be extrapolated onto human disease. 
4.5.3 Use of ncRNA therapies 
Much evidence points towards that ncRNA-therapies are indeed possible and could break 
ground for therapeutic approaches that have not been possible or feasible before (further 
discussed in the following section). While not explicitly ncRNA-based, the mRNA-based 
COVID-19 vaccines have certainly accelerated interest in nucleotide-based therapies. 
Yet, while the actions of mRNA are known and more or less straightforward, we are still far 
from a complete understanding of all the roles that ncRNAs play in human biology. It is still 
common for new mechanisms of function to be described for already characterized lncRNAs. 
The relative novelty of the field and consequently our still limited understanding of lncRNA 
action mechanisms raises the potential for unexpected adverse effects. Here, we believe that 
targeted local delivery of potential lncRNA therapeutics might be an important tool to 
overcome these obstacles. In addition, many ncRNAs tend to be expressed in relatively low 
concentrations during physiological states. In contrast, when supplying additional exogenous 
ncRNAs as a treatment strategy, these are often delivered in supraphysiological concentrations, 
many orders of magnitude higher than what could be achieved through the intracellular 
processes of their synthesis. Perhaps for this reason, the majority of RNA therapeutics that are 
approved by the FDA/EMA or are undergoing phase II/III trials, are ASO based, and function 
through inhibition of target genes [336].
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5 POINTS OF PERSPECTIVE 
A lot of resources in the past decades have been dedicated to gaining a better understanding of 
the critical processes that drive vascular disease [337]. While the studies in this thesis have 
looked at two correlated but seemingly different [338] vascular pathologies – atherosclerosis 
and AAA, the critical role that VSMCs play in these diseases has undoubtedly emerged as a 
common theme. The recent studies of diseased-state VSMC origins, aided by the advancements 
of in vivo cellular lineage-tracing technologies, have reaffirmed the long-existing suspicion that 
these cells heavily contribute to disease phenotypes [57, 59, 68, 71, 80, 92, 94, 339, 340].  
Looking at atherosclerosis, successful therapeutic approaches have been focused on regulating 
lipid metabolism and/or reducing inflammation [341, 342]. Meanwhile, no pharmacological 
treatment is available for patients with AAA [343]. This is especially problematic for patients 
with small, asymptomatic AAAs or patients who for other reasons are not candidates for 
surgical treatment. Effective medical therapies could also help avoid risks associated with 
surgical AAA repair. Given the vast importance VSMC dynamics seem to play in these 
pathologies, treatment strategies targeting VSMC phenotypic modulation seem promising. In 
the cancer field, the leader of experimental therapeutic efforts, many treatments have been 
focused on inhibiting protein interactions through antibody-based therapies or small molecules. 
Transcription factors, enzymes, and signaling pathways, involved in vascular disease are 
feasible targets for novel treatment approaches. An example of such a treatment is evolocumab, 
a monoclonal antibody that targets PCSK9, approved for clinical use in 2015 [344]. Inhibition 
of PCSK9 increases the expression of LDL-receptors in the liver, resulting in a striking 
decrease of circulating LDL-particles. However, there are also many feasible targets with 
potential protective functions. An example of such a target is FGF2 (evaluated in study II), 
known to positively affect VSMC proliferation and survival [345, 346]. Induction of increased 
expression of these targets is not possible through the aforementioned approaches. 
RNA-based therapeutics provide a potential solution to this problem, with a number of RNA-
interference-based therapeutics currently being evaluated in phase II and III clinical trials [336]. 
By targeting lncRNAs such as NATs (e.g. NUDT6 in study II), expression of mRNA partners 
can be de-repressed and increased protein expression induced. No clinical trials have yet been 
initiated for lncRNAs, but several newly discovered lncRNAs with the ability to regulate the 
phenotype of VSMCs certainly seem like promising targets. 
Systemic treatments can only be developed against targets that are either: a) specific to a 
particular tissue, b) have actions that are uniformly beneficial or detrimental in all types of 
tissues, or c) where the significant adverse effects can be tolerated – e.g. anti-cancer drugs. A 
potential solution to this problem is targeted drug delivery, demonstrated in studies II and III 
through DEBs or ultrasound targeted microbubble destruction (UTMD). While certain VSMC-
specific lncRNAs (e.g. CARMN) exist, several CVD-relevant lncRNAs are expressed in other 
tissues [261, 263]. Without targeted drug delivery, many treatments are likely to fail due to 
undesirable adverse effects. 
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The academic community is currently suffering from a ‘reproducibility crisis’ [347]. This term 
pertains mainly to the inability to reproduce research findings using identical or similar 
methods. However, there is also a translational aspect to this problem. The development of 
potential therapeutics is highly dependent on the ability to bridge results of in vitro and in vivo 
studies into clinical practice. Today, most researchers are hopefully aware that findings in 
murine models do not necessarily translate into human pathologies [348]. Nonetheless, many 
of these results are often taken for granted when describing the state of knowledge within the 
field. To truly understand the pathologies in question, better disease models are required. 
Translational animal models (such as the LDLR-/- Yucatan mini-pig model of atherosclerosis 
and AAA used in studies I, II, and III) are only one aspect of this. More relevant in vitro 
approaches and techniques are just as important. This can be performed through the use of 
patient cells (as in studies II and III), through better matching of patient and control tissues 
(studies II and IV), but also in many other ways – e.g. organs-on-chips, organoids, and other 
advanced cell co-culture approaches [349]. 
Not only medical therapeutics can be targeted better. Currently, in many cases, it is difficult to 
know ahead of time how much a patient will benefit from the surgical treatment and whether 
this exceeds the dangers associated with surgery. This is true for AAA repair (small aneurysms, 
women patients, older/fragile patients) as well as for CEA (asymptomatic carotid stenosis, low-
moderate symptomatic carotid stenosis). The positive outcomes are also measured for a whole 
group of patients. What this means is that many (if not the majority) of these patients would 
not have adverse effects without surgical intervention. However, it is currently impossible to 
risk-stratify them closer than on a group level. Therefore, much can be gained from developing 
novel tools of risk stratification. A better selection of patients to undergo intervention would 
lead to fewer adverse events and likely to significant cost-savings – resources that can be 
repurposed for the care of patients who need it most. This is especially true for countries with 
underdeveloped healthcare systems or without universal healthcare, where the ability to treat 
certain patient groups is limited by economic factors. 
Ultrasound-based screening for AAA is a cost-efficient way of preventing AAA-rupture-
related deaths. However, its effectiveness diminishes in the absence of risk factors such as 
smoking or male sex [125, 129, 331]. Much effort has been put into studying potential protein 
biomarkers [194]. Although several seem promising, none are yet close to being used in clinical 
practice [194]. The fact that ncRNAs are involved in AAA disease and abundant in circulation 
makes them interesting and promising targets. The constant development of novel genomic 
technologies is likely to eventually allow for the screening of many different ncRNAs, an 
approach that may turn out more powerful and sensitive than existing proteomic approaches. 
miRNAs seem like promising disease biomarkers, given their ability to regulate whole 
networks of genes (as is the case for miR-15a in study IV) and their ease of detection in 
circulation. Many potential ncRNA biomarkers have been implicated in cancer [350, 351], and 
there is no reason to believe this will not be the case in CVD. 
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6 CONCLUSIONS 
The overall aim of this thesis was to evaluate the role and therapeutic potential of novel 
ncRNAs associated with AAA disease development and progression. Through the constituent 
studies we were able to conclude the following: 
Study I. Long non-coding RNA MIAT has is able to regulate proliferation and 
transdifferentiation of arterial smooth muscle cells and inflammatory activity in 
macrophages during atherosclerotic plaque development and progression. 
 
Study II. Natural antisense transcript NUDT6 is able to regulate SMC survival in vitro, 
through its inhibition of growth factor FGF2. NUDT6-inhibition is a successful 
treatment approach in advanced pre-clinical models of plaque rupture and AAA. 
 
Study III. Local treatment with lenvatinib is able to inhibit AAA progression in vivo in 
both murine and translational porcine animal models, through the restoration of 
VSMCs contractility. 
 
Study IV. miR-15a is a disease-relevant circulating biomarker of AAA, and its increased 
expression in AAA patient aortas has a pro-inflammatory effect on VSMCs. 
Inhibition of miR-15a in the murine PPE model of AAA augments diameter 
growth. 
An additional conclusion of studies II and III is that local delivery of ncRNA-therapeutics 
through either DEBs or UTMD-delivery is a feasible therapeutic approach for the treatment of 
AAA and likely also feasible for the treatment of advanced atherosclerotic lesions.
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